<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006390.pub2" GROUP_ID="LIVER" ID="138106011011253006" MERGED_FROM="" MODIFIED="2016-09-09 12:32:22 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2016-09-09 13:27:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2011-05-10 18:08:30 +0200" MODIFIED_BY="[Empty name]">Non-steroid anti-inflammatory drugs for biliary colic</TITLE>
<CONTACT>
<PERSON ID="11495" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Mirella</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fraquelli</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Gastroenterologist</POSITION>
<EMAIL_1>mfraquelli@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+39 338 6733495</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastroenterology and Endoscopy Unit</DEPARTMENT>
<ORGANISATION>Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, Università degli Studi di Milano</ORGANISATION>
<ADDRESS_1>Via F. Sforza, 35</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20122</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>++390255033369</PHONE_1>
<PHONE_2/>
<FAX_1>++390250320410</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-09-09 13:27:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="11495" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Mirella</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fraquelli</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Gastroenterologist</POSITION>
<EMAIL_1>mfraquelli@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+39 338 6733495</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastroenterology and Endoscopy Unit</DEPARTMENT>
<ORGANISATION>Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, Università degli Studi di Milano</ORGANISATION>
<ADDRESS_1>Via F. Sforza, 35</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20122</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>++390255033369</PHONE_1>
<PHONE_2/>
<FAX_1>++390250320410</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9708AA4382E26AA20165AC2EE764A66D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Casazza</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>giovanni.casazza@unimi.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Dipartimento di Scienze Biomediche e Cliniche "L. Sacco"</DEPARTMENT>
<ORGANISATION>Università degli Studi di Milano</ORGANISATION>
<ADDRESS_1>via GB Grassi 74</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20157</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0250319653</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0250319656</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="906FD81582E26AA2010A53142F8254E2" ROLE="AUTHOR">
<PREFIX>Professor</PREFIX>
<FIRST_NAME>Dario</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Conte</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Director and Chief</POSITION>
<EMAIL_1>dario.conte@unimi.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Gastroenterology and Endoscopy Unit</DEPARTMENT>
<ORGANISATION>Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, Università degli Studi di Milano</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20122</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 02 5503 3418</PHONE_1>
<PHONE_2/>
<FAX_1>+39 02 5523 3644</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11480" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Agostino</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Colli</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>a.colli@asst-lecco.it</EMAIL_1>
<EMAIL_2>so.colombo@ospedale.lecco.it</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>A Manzoni Hospital ASST Lecco</ORGANISATION>
<ADDRESS_1>Via dell'Eremo, 9/11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lecco</CITY>
<ZIP>23900</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0341 489 670</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0341 489 671</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-07-28 11:21:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="15" MONTH="7" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="7" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="7" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="9" YEAR="2016"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2009-01-20 16:45:04 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<HISTORY MODIFIED="2009-09-01 13:34:51 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2016-04-21 09:42:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<INTERNAL_SOURCES MODIFIED="2016-04-21 09:42:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SOURCE MODIFIED="2016-04-21 09:42:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<NAME>Università degli Studi di Milano, Milan</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2016-04-21 09:41:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<NAME>A Manzoni Hospital ASST Lecco, Lecco</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-09-09 12:30:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2016-09-08 16:28:13 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-03-02 11:22:56 +0100" MODIFIED_BY="Dimitrinka Nikolova">Non-steroid anti-inflammatory drugs for biliary colic</TITLE>
<SUMMARY_BODY MODIFIED="2016-09-08 16:28:13 +0200" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;&lt;span modified=&quot;2016-09-07 00:26:53 -0700&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;NSAIDs also &lt;/span&gt;&lt;span modified=&quot;2016-09-07 00:26:53 -0700&quot; modified_by=&quot;[Empty name]&quot; class=&quot;insertedmarker&quot;&gt;significantly reduced cholelithiasis-related complications (e.g. acute cholecystitis, acute pancreatitis, jaundice, cholangitis) as compared to placebo&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2016-09-07 00:26:00 -0700&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;(this confli&lt;/span&gt;&lt;span modified=&quot;2016-09-07 00:27:00 -0700&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;cts with the Effects of interventions section)&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-09-08 16:28:13 +0200" NOTES_MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Background</B>
</P>
<P>Non-steroid anti-inflammatory drugs (NSAIDs) such as diclofenac, ketorolac, tenoxicam, flurbiprofen, etc. are commonly used to relieve biliary colic pain.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched for randomised clinical trials recruiting participants presenting with biliary colic and comparing NSAIDs versus no intervention, placebo, or other drugs.</P>
<P>
<B>Key results</B>
</P>
<P>We included 12 randomised clinical trials with 828 participants, of whom 416 received NSAIDs and 412 received placebo, spasmolytic drugs, or opioids, in the review. Considering the common occurrence of biliary colic, these numbers of trials and participants are insufficient. Elderly participants and participants with co-morbidities were poorly represented in the trials. Twenty-four per cent of the participants were males. The age of participants ranged from 18 to 86 years. All people were admitted to emergency department for acute biliary pain. There was no mortality. None of the included trials reported quality of life. We found that NSAIDs significantly reduced biliary pain when compared with placebo and spasmolytic drugs. NSAIDs also significantly reduced cholelithiasis-related complications (e.g. acute cholecystitis, acute pancreatitis, jaundice, cholangitis) as compared to placebo and spasmolytic drugs. One trial comparing NSAIDs versus opioids reported results on complications, finding no significant difference between treatments.</P>
<P>None of the trials reported major adverse events. Seven out of 12 trials reported minor adverse events; in two out of the eight trials adverse events were not observed, and minor events were reported in the remaining five trials.</P>
<P>We found one ongoing randomised clinical trial aimed at assessing the analgesic effectiveness of intravenous ibuprofen in biliary colic.</P>
<P>
<B>Funding</B>
</P>
<P>The trials appeared to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design, conductance, results, or conclusions of the trial.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>The quality of evidence according to GRADE criteria (a system developed to grade evidence and recommendations in health care) was moderate for the comparison NSAIDs versus placebo for the outcome lack of pain relief and low or very low for the other outcomes and comparisons.</P>
<P>Only one of 12 trials was at low risk of bias following predefined 'Risk of bias' domains.</P>
<P>The results of the present systematic review with meta-analysis suggest that NSAIDs can be used for pain relief, but further randomised clinical trials are warranted, and NSAIDs should be used with care in certain patient groups, such as the elderly and people with co-morbidities.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-09-08 16:27:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2016-09-07 12:58:07 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cholelithiasis refers to the presence of gallstones, which are concretions that form in the biliary tract, usually in the gallbladder. Cholelithiasis is one of the most common surgical problems worldwide and is particularly prevalent in most Western countries.</P>
<P>Biliary colic is the term used for gallbladder pain experienced by a person with gallstones and without overt infection around the gallbladder. It is the most common manifestation of cholelithiasis, observed in over one-third of people with gallstones over the course of 10 or more years. Non-steroid anti-inflammatory drugs (NSAIDs) have been widely used to relieve biliary colic pain, but their role needs further elucidation. They may decrease the frequency of short-term complications, such as mild form of acute cholecystitis, jaundice, cholangitis, and acute pancreatitis, but they may also increase the occurrence of more severe and possibly life-threatening adverse events such as gastrointestinal bleeding, renal function impairment, cardiovascular events, or milder events such as abdominal pain, drowsiness, headache, dizziness, or cutaneous manifestations.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-04-07 16:51:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the benefits and harms of NSAIDs in people with biliary colic.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-09-07 12:58:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the Cochrane Hepato-Biliary Controlled Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE (Ovid SP), Embase (Ovid SP), Science Citation Index Expanded (Web of Science), and ClinicalTrials.gov until July 2016. We applied no language limitation.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-02-13 10:19:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trials recruiting participants presenting with biliary colic and comparing NSAIDs versus no intervention, placebo, or other drugs.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-09-07 12:58:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors (MF and AC) independently identified trials for inclusion. We used risk ratios (RR) to express intervention effect estimates, and we analysed the data with both fixed-effect and random-effects model meta-analyses, depending on the amount of heterogeneity. We controlled random errors with Trial Sequential Analysis. We assessed the methodological quality of the evidence using GRADE criteria.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-09-08 11:54:00 +0200" MODIFIED_BY="[Empty name]">
<P>Twelve randomised clinical trials (RCTs) met our predefined review protocol criteria for analysis. We found only one trial to be at low risk of bias, considering the remaining trials to be at high risk of bias. The risk of selection bias in nine studies was unclear due to poor reporting, leading to uncertainty in the pooled effect estimates. Five trials compared NSAIDs versus placebo, four trials compared NSAID versus opioids, and four trials compared NSAID versus spasmolytic drugs (one of the 12 trials was a three-arm study comparing NSAIDs versus both opioids and spasmolytic drugs). There were 828 randomised participants (minimum 30 and maximum 324 per trial), of whom 416 received NSAIDs and 412 received placebo, spasmolytic drugs, or opioids. Twenty-four per cent of the participants were males. The age of the participants in the trials ranged from 18 to 86 years. All people were admitted to emergency departments for acute biliary pain. There was no mortality. When compared with placebo, NSAIDs obtained a significantly lower proportion of participants without complete pain relief (RR 0.27, 95% confidence interval (CI) 0.19 to 0.40; I<SUP>2 </SUP>= 0%; 5 trials; moderate-quality evidence), which was confirmed by Trial Sequential Analysis, but not regarding participants with complications (RR 0.66, 95% CI 0.38 to 1.15; I<SUP>2</SUP> = 26%; 3 trials; very low-quality evidence). NSAIDs showed more pain control than spasmolytic drugs (RR 0.51, 95% CI 0.37 to 0.71; I<SUP>2 </SUP>= 0%; 4 trials; low-quality evidence), which was not confirmed by Trial Sequential Analysis, and a significantly lower proportion of participants with complications (RR 0.27, 95% CI 0.12 to 0.57; I<SUP>2 </SUP>= 0%; 2 trials; low-quality evidence), which was also not confirmed by Trial Sequential Analysis. We found no difference in the proportions of participants without complete pain relief when comparing NSAIDs versus opioids (RR 0.98, 95% CI 0.47 to 2.07; I<SUP>2</SUP> = 52%), suggesting moderate heterogeneity among trials (4 trials; very low-quality evidence). Only one trial comparing NSAIDs versus opioids reported results on complications, finding no significant difference between treatments. None of the included trials reported severe adverse events. Seven out of the 12 trials assessed non-severe adverse events: in two out of the seven trials, adverse events were not observed, and minor events were reported in the remaining five trials.</P>
<P>In addition, we found one ongoing RCT assessing the analgesic efficacy of intravenous ibuprofen in biliary colic.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-09-07 12:59:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>NSAIDs have been assessed in relatively few trials including a limited number of participants for biliary colic, considering its common occurrence. We found only one trial to be at low risk of bias. There was no mortality. None of the included trials reported quality of life. The generalisability of the review is low as most of the RCTs included neither elderly people nor participants with comorbidities, who are more prone to complications as compared to others with biliary colic.</P>
<P>The beneficial effect of NSAIDs compared with placebo on pain relief was confirmed when we applied Trial Sequential Analysis.</P>
<P>The quality of evidence according to GRADE criteria was moderate for the comparison of NSAIDs versus placebo regarding the outcome lack of pain relief and low or very low for the other outcomes and comparisons.</P>
<P>We found only one trial at low risk of bias, following the predefined 'Risk of bias' domains. We found the risk of selection bias to be unclear in nine studies due to poor reporting, leading to uncertainty in the pooled effect estimates.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-09-09 12:30:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2016-09-09 11:45:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CONDITION MODIFIED="2016-09-07 13:01:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cholelithiasis refers to the presence of gallstones, which are concretions that form in the biliary tract, usually in the gallbladder. Cholelithiasis represents one of the most common surgical problems worldwide and is especially prevalent in most Western countries. In the USA alone, gallstones are present in 8% to 20% of the population by the age of 40 years, and are more likely to develop in women than in men by a ratio of between 2 and 3 to 1 (<LINK REF="REF-Friedman-1993" TYPE="REFERENCE">Friedman 1993</LINK>; <LINK REF="REF-Johnson-2001" TYPE="REFERENCE">Johnson 2001</LINK>). Mexican-Americans and American Indians also seem to have an increased risk for the development of gallstones, and in all cultures, the incidence increases as age increases.</P>
<P>A population of male civil servants in Rome, Italy, was investigated to determine the prevalence of symptomatic and asymptomatic gallstone disease. In this study, in which 71.5% of the population participated, the prevalence of gallstone disease was 8.2%, and increased from 2.3% in the 20- to 25-year-old age group to 14.4% in the 60- to 69-year-old age group, based on both presence of gallstones and history of cholecystectomy. About one-third of the men with gallstone disease had previously been submitted to cholecystectomy. Overall, 7.7% of the men with presence of gallstones had complained of at least one episode of biliary pain in the preceding five years (<LINK REF="REF-Grepco-I-1988" TYPE="REFERENCE">Grepco I 1988</LINK>). In another, more recent study performed in a random sample of women belonging to a rural population, during a 10-year longitudinal follow-up, the overall 10-year incidence of gallstone disease was 6.3% (5.5% of new gallstones and 0.8% of cholecystectomies) (<LINK REF="REF-Angelico-1997" TYPE="REFERENCE">Angelico 1997</LINK>). More than three-quarters (76.9%) of these women had not suffered biliary pain (<LINK REF="REF-Angelico-1997" TYPE="REFERENCE">Angelico 1997</LINK>). Out of the initially asymptomatic gallstone women, 15.4% experienced at least one episode of biliary pain, 23.1% underwent elective cholecystectomy, and 61.5% remained asymptomatic (<LINK REF="REF-Grepco-II-1988" TYPE="REFERENCE">Grepco II 1988</LINK>). The GREPCO study reported a cumulative probability of developing biliary colic in initially asymptomatic people of 11.9 ± 3.0% at two years and 25.8 ± 4.6% at 10 years (<LINK REF="REF-Attili-1995" TYPE="REFERENCE">Attili 1995</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-09-07 13:01:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Non-steroid anti-inflammatory drugs (NSAIDs), opioid drugs, and spasmolytic drugs have been widely used to relieve biliary colic. NSAIDs are usually used as the first line of treatment.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-09-09 11:45:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>NSAIDs' pathophysiological mechanism of relieving pain is thought to be related not only to their anti-inflammatory action, but also to their smooth-muscle relaxant capacities (<LINK REF="REF-Thornell-1985" TYPE="REFERENCE">Thornell 1985</LINK>; <LINK REF="REF-Goldman-1989" TYPE="REFERENCE">Goldman 1989</LINK>; <LINK REF="REF-Brooks-1998" TYPE="REFERENCE">Brooks 1998</LINK>; <LINK REF="REF-Morgan-1999" TYPE="REFERENCE">Morgan 1999</LINK>). However, the actual role of NSAIDs in biliary colic has yet to be clarified. It remains unclear whether NSAIDs decrease or increase the frequency of short-term complications caused by gallstones. Simultaneously, NSAIDs may increase the risk for more severe adverse events, including those that are life-threatening. For instance, NSAIDs interfere with platelet function, and thus may increase the risk of bleeding after interventions such as surgery or endoscopic retrograde cholangiopancreatography (ERCP).</P>
<P>The usual first-line treatment for biliary colic is NSAIDs, but other drugs can also be used. Opioid drugs include morphine, codeine, and pethidine, which reduce the intensity of pain signals reaching the brain and affect those brain areas that control emotion, in this way diminishing the effects of a painful stimulus. Spasmolytic drugs such as hyoscine butylbromide (also known as scopolamine) inhibit the action of acetylcholine and stop the transmission of parasympathetic nerve impulses, thus lessening the spasms of the smooth muscle in the gastrointestinal tract and in the gallbladder.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-09-08 16:55:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cholelithiasis is one of the most common surgical problems worldwide and is especially prevalent in Western countries. Biliary colic is the most common manifestation of cholelithiasis, developing in at least one-third of people with gallbladder stones over a 10-year follow-up period. NSAIDs have been widely used to relieve biliary colic pain, but their role needs further elucidation. NSAIDs may decrease the frequency of short-term complications caused by gallstones, such as a mild form of acute cholecystitis, jaundice, cholangitis, and acute pancreatitis, but they may simultaneously increase the risk of more severe and possibly life-threatening events such as gastrointestinal bleeding, renal function impairment, cardiovascular events, or milder events such as abdominal pain, drowsiness, headache, dizziness, or cutaneous manifestations.</P>
<P>There are only two non-Cochrane systematic reviews with meta-analyses so far available. The first Spanish review compared NSAIDs versus other drugs for biliary colic in people with cholelithiasis (<LINK REF="REF-Basurto-Ona-2008" TYPE="REFERENCE">Basurto Ona 2008</LINK>), and included seven randomised clinical trials with 349 participants (<LINK REF="STD-Niinikoski-1984" TYPE="STUDY">Niinikoski 1984</LINK>; <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>); all but one of these trials are included in our review (<LINK REF="STD-Niinikoski-1984" TYPE="STUDY">Niinikoski 1984</LINK>). We excluded <LINK REF="STD-Niinikoski-1984" TYPE="STUDY">Niinikoski 1984</LINK> from our review because it compared two NSAIDs (indomethacin 50 mg and metamizole 2.5 g). The second non-Cochrane review was published by our own group (<LINK REF="REF-Colli-2012" TYPE="REFERENCE">Colli 2012</LINK>). In this review, we did not grade the overall evidence and did not perform a Trial Sequential Analysis to calculate the cumulative sample size of the meta-analysis (information size), thus running the risk of overestimating the efficacy of NSAIDs in reducing biliary colic complications.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-02-11 18:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of NSAIDs in people with biliary colic.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-09-08 16:56:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2016-09-07 13:02:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2016-09-07 13:02:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials evaluating the possible benefits and harms of NSAIDs in people with biliary colic. We included the trials irrespective of blinding, year of publication, publication status, or language.</P>
<P>For evaluation of harms, we included quasi-randomised clinical studies and observational studies identified during our searches for randomised clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-03-04 12:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>All people presenting with biliary colic according to the definitions and diagnostic work-up in the individual trials.<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-08-16 17:00:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We considered all types of NSAIDs as the experimental intervention. We considered no intervention, placebo, or other drugs (e.g. opioid, spasmolytic drugs) as control interventions, independently of their route or schedule of administration.<BR/>
<BR/>We allowed collateral interventions if received equally by all participants in the trial.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-09-07 13:02:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-09-05 07:36:46 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Mortality.</LI>
<LI>Lack of pain relief. Number of people not experiencing pain relief out of all the people treated as defined in the primary studies.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-09-07 13:02:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>Number of people with cholelithiasis-related complications (e.g. acute cholecystitis, acute pancreatitis, jaundice, cholangitis; number of people manifesting bleeding from operative intervention or ERCP less than 9, or both).</LI>
<LI>Quality of life.</LI>
<LI>Drug-related complications and adverse events, the latter expressed as the number of people experiencing any event (e.g. gastrointestinal bleeding, cutaneous rash, renal function impairment, cardiovascular events, or any other events described in the trials).</LI>
<LI>Quantification of pain relief rated in the trials on quantitative scales.</LI>
<LI>The time needed to obtain pain relief: complete pain relief or any small amount of pain relief (as defined by the different trials).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-09-08 16:55:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2016-09-08 16:55:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (<LINK REF="REF-Gluud-2016" TYPE="REFERENCE">Gluud 2016</LINK>; 31 July 2016)<I>,</I> Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 5) in the Cochrane Library, MEDLINE (OvidSP; 1946 to 31 July 2016), Embase (OvidSP; 1974 to 31 July 2016), Science Citation Index Expanded (Web of Science; 1900 to 31 July 2016) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>), and ClinicalTrials.gov (www.clinicaltrials.gov) (31 July 2016). We also searched ClinicalTrials.gov for ongoing studies. The search strategies used and time spans of the searches can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-09-07 13:04:06 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the proceedings of the major hepatological and surgical congresses and references of included trials. In cases where the full paper could not be retrieved or there were uncertainties, we contacted the authors of the study.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-09-08 16:56:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_SELECTION MODIFIED="2016-09-08 12:16:26 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors (MF, AC) read the abstract of each study identified by the search, eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. The same review authors then independently read these studies to determine eligibility; any disagreements were settled by discussion, and reasons for exclusion were recorded. The two review authors were unblinded with regard to the names of the authors, investigators, institution, source, and results.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-09-07 13:04:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We designed standardised extraction sheets and piloted one before use. Two review authors (AC, MF) independently extracted data from the included trials. The extracted data included:</P>
<UL>
<LI>participant characteristics: age, sex;</LI>
<LI>experimental and control interventions (see above);</LI>
<LI>outcomes (see above);</LI>
<LI>trial quality characteristics (see below).</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-09-07 13:07:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors (MF, GC) independently assessed the risk of bias of each included trial according to the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2016" TYPE="REFERENCE">Gluud 2016</LINK>), and methodological studies (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovi_x0107_-2012" TYPE="REFERENCE">Savovi&#263; 2012</LINK>; <LINK REF="REF-Savovi_x0107_-2012a" TYPE="REFERENCE">Savovi&#263; 2012a</LINK>).</P>
<P>We used the following definitions in the 'Risk of bias' assessment.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial.</LI>
<LI>Uncertain risk of bias: the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method was not random.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel</HEADING>
<UL>
<LI>Low risk of bias: it was mentioned that both participants and personnel providing the interventions were blinded, and the method of blinding was described, so that knowledge of allocation was prevented during the trial.</LI>
<LI>Unclear risk of bias: it was not mentioned if the trial was blinded, or the trial was described as blinded, but the method or extent of blinding was not described, so that knowledge of allocation was possible during the trial.</LI>
<LI>High risk of bias: the trial was not blinded, so that the allocation was known during the trial.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinded outcome assessment</HEADING>
<UL>
<LI>Low risk of bias: it was mentioned that outcome assessors were blinded, and the method of blinding was described, so that knowledge of allocation was prevented during the trial.</LI>
<LI>Unclear risk of bias: it was not mentioned if the trial was blinded, or the trial was described as blinded, but the method or extent of blinding the assessors was not described, so that knowledge of allocation was possible during the trial.</LI>
<LI>High risk of bias: the trial was not blinded, so that the allocation was known to the assessors during the trial.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data.</LI>
<LI>Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk: the trial reported outcomes such as mortality; lack of complete pain relief; and number of people with cholelithiasis-related complications, drug-related complications, and adverse events. If the original trial protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g. ClinicalTrials.gov), the outcomes sought should have been those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes will not be considered to be reliable.</LI>
<LI>Unclear risk: not all predefined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk: one or more predefined outcomes were not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for-profit support that could manipulate the trial design, conductance, or results of the trial.</LI>
<LI>Uncertain risk of bias: the trial may or may not be free of for-profit bias, as no information on clinical trial support or sponsorship was provided.</LI>
<LI>High risk of bias: the trial was sponsored by industry or received other type of for-profit support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other sources of bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other factors that could put it at risk of bias.</LI>
<LI>Uncertain risk of bias: the trial may or may not have been free of other factors that could put it at risk of bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias.</LI>
</UL>
<P>Review authors MF and AC judged trials to be at low risk of bias if they were assessed as having low risk of bias in all of the above domains. In all other cases, we judged the trials to be at high risk of bias. We resolved any differences in opinion through discussion; in the case of unsettled disagreements, review authors GC and DC adjudicated.</P>
<P>We summarised results in both a 'Risk of bias' graph and a 'Risk of bias' summary.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-09-07 13:08:03 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We presented dichotomous data as risk ratio (RR) with 95% confidence interval (CI) and continuous outcomes as mean differences (MD) with 95% CI.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-07-25 10:38:06 +0200" MODIFIED_BY="[Empty name]">
<P>The randomised participants in the trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-09-07 13:08:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We contacted investigators of the trials to request missing data. We performed all analyses according to the intention-to-treat analysis method, that is analysing participants in the trials in the groups to which they were randomised, regardless of whether they had received or adhered to the allocated intervention.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-09-07 13:08:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We explored the presence of statistical heterogeneity by the Chi<SUP>2</SUP> test, with significance set at P value of less than 0.10. In case of significant heterogeneity, we explored the possible sources of heterogeneity by means of sensitivity analyses. In addition, we used the I<SUP>2</SUP> statistic to quantify the heterogeneity according to the following classification: from 0% to 40%, heterogeneity may not be important; from 30% to 60%, heterogeneity may be moderate; from 50% to 90%, heterogeneity may be substantial; and from 75% to 100%, heterogeneity may be considerable.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-09-07 13:08:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>For any considered outcome where at least 10 trials were included in the meta-analysis, we tested for funnel plot asymmetry (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-09-07 13:08:41 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Meta-analysis</HEADING>
<P>We performed meta-analyses following the recommendations reported in the <I>Cochrane Handbook for Systematic Reviews of Intervention</I> and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Gluud-2016" TYPE="REFERENCE">Gluud 2016</LINK>).</P>
<P>We applied both fixed-effect model, <LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>, and random-effects model, <LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>, meta-analyses. If there were statistically significant discrepancies in the results, we reported both analyses. Otherwise, we reported the results obtained with the fixed-effect model when heterogeneity was substantially absent (I<SUP>2</SUP> less than 10%) and reported the results obtained by the random-effects model when heterogeneity was present.</P>
<P>We used the statistical package provided with Review Manager 5 for the meta-analysis (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial Sequential Analysis</HEADING>
<P>We performed Trial Sequential Analysis to calculate the cumulative sample size of the meta-analysis (information size) and to reduce the risk of random errors due to sparse data and repetitive testing of the accumulating data (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). When conducting a meta-analysis, significance testing may be performed each time a new trial is added. Similar to multiple interim analyses in a single clinical trial, repetitive testing in a meta-analysis increases the risk of type I error. The assumption underlying Trial Sequential Analysis is that testing for significance may be performed each time a new trial is added to the meta-analysis, resulting in an increased risk of random errors. For this reason, a statistical approach that controls the overall risk of type I error is needed. We calculated the information size adjusted for heterogeneity (diversity, D<SUP>2</SUP>) between trials using the following parameters (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>): the proportion of events in the control group estimated from the included trials (overall mean value); anticipated intervention effect (relative risk reduction, RRR) of 20%; risk of type I error (&#945;) of 0.05; power of 0.80. We added trials to the analysis according to the year of publication. If more than one trial was published in a year, we added the trials in alphabetical order, according to the name of the first author. On the basis of the required information size, we constructed the trial sequential monitoring boundaries for benefits and futility using the O'Brien-Fleming alpha spending (for benefit) and beta-spending (for futility) functions. The boundaries for benefit are used in case of meta-analyses that have not reached the required information size to conclude when statistical significance is reached. If the trial sequential monitoring boundary is crossed before the required information size is reached, a sufficient level of evidence is reached, the results of the meta-analysis can be considered conclusive if bias can be excluded, and no additional trials may be needed. Conversely, if the boundary is not crossed, the meta-analysis is inconclusive, and more trials may be needed in order to detect or reject a certain intervention effect. When the cumulative Z-curve crosses the futility boundaries, a sufficient level of evidence is reached that the two treatments do not differ more than 20% (the anticipated intervention effect used in information size estimation), and no additional trials may be needed. In all situations where no trial sequential monitoring boundaries are reached, further studies may be needed until the information size is reached or monitoring boundaries are crossed.</P>
<P>We performed Trial Sequential Analysis with the Trial Sequential Analysis software, version 0.9 beta (<LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-09-08 16:56:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We considered the following for subgroup analyses.</P>
<UL>
<LI>Sex.</LI>
<LI>Participant age.</LI>
<LI>Number of biliary colic attacks experienced before entry.</LI>
<LI>Setting in which the trial was done (i.e. emergency unit or primary, secondary, or tertiary care unit).</LI>
<LI>Type of NSAIDs used in the trial.</LI>
<LI>Dosage of anti-inflammatory drug used in the trial.</LI>
<LI>Route of administration of the drug.</LI>
<LI>Duration of follow-up.</LI>
<LI>Risk of bias.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-09-08 16:37:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned no sensitivity analyses.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>The 'Summary of findings' tables show the proportion of people with lack of pain relief for the three comparisons that have been analysed (NSAIDs versus placebo; NSAIDs versus spasmolytic drugs; NSAIDs versus opioid drugs) and their corresponding RR (with their 95% CI), and the proportion of people with cholelithiasis-related complications only for the comparison NSAIDs versus placebo, with its corresponding RR (95% CI).</P>
<P>We used the GRADE system to assess the quality of evidence and to build the 'Summary of findings' tables for the outcomes considered in this review. We used the GRADEpro 3.6 software (<A HREF="http://tech.cochrane.org/revman/gradepro">tech.cochrane.org/revman/gradepro</A>) to construct <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>, and <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within-study risk of bias, indirectness of the evidence, heterogeneity of the data, imprecision of effect estimates (wide CIs and as evaluated with our Trial Sequential Analysis) (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>), and risk of publication bias (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>; <LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>; <LINK REF="REF-Guyatt-2011f" TYPE="REFERENCE">Guyatt 2011f</LINK>; <LINK REF="REF-Guyatt-2011g" TYPE="REFERENCE">Guyatt 2011g</LINK>; <LINK REF="REF-Guyatt-2013" TYPE="REFERENCE">Guyatt 2013</LINK>; <LINK REF="REF-Mustafa-2013" TYPE="REFERENCE">Mustafa 2013</LINK>; <LINK REF="REF-Guyatt-2013a" TYPE="REFERENCE">Guyatt 2013a</LINK>; <LINK REF="REF-Guyatt-2013b" TYPE="REFERENCE">Guyatt 2013b</LINK>; <LINK REF="REF-Guyatt-2013c" TYPE="REFERENCE">Guyatt 2013c</LINK>).</P>
<P>We defined the levels of evidence as 'high', 'moderate', 'low', or 'very low' as follows.</P>
<UL>
<LI>High certainty: this research provides a very good indication of the likely effect; the likelihood that the effect will be substantially different is low.</LI>
<LI>Moderate certainty: this research provides a good indication of the likely effect; the likelihood that the effect will be substantially different is moderate.</LI>
<LI>Low certainty: this research provides some indication of the likely effect; however, the likelihood that it will be substantially different is high.</LI>
<LI>Very low certainty: this research does not provide a reliable indication of the likely effect; the likelihood that the effect will be substantially different is very high.</LI>
</UL>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-09-09 12:15:57 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2016-09-09 11:38:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SEARCH_RESULTS MODIFIED="2016-09-09 11:38:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified a total of 278 references through electronic searches of the Cochrane Hepato-Biliary Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and Science Citation Index Expanded until 31 July 2016. We identified two publications through manual searching. Overall, we excluded 266 references: 264 were clearly irrelevant to the present systematic review, having read abstracts in 258 cases and the full text of six of these publications, two were duplicates. We have listed the six excluded studies in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table with reasons for exclusion. A PRISMA flow diagram is provided in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>The remaining 12 references were reports of 12 randomised trials, and they fulfilled our inclusion criteria. The trials included a total of 828 participants, of whom 416 received NSAIDs and 412 served as controls (receiving placebo or opioids or spasmolytic drugs). We have provided details of the included trials in <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>. All trials used a parallel-group design. One of the trials had three parallel groups.</P>
<P>We also found one ongoing study that aims to assess the analgesic efficacy of intravenous ibuprofen in biliary colic.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-09-07 13:10:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We have provided a detailed description of the included trials in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trials</HEADING>
<P>All of the included trials were randomised clinical trials with parallel-group design. In one of the included trials (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>), NSAIDs were compared with both opioids and spasmolytic drugs.</P>
<SUBSECTION>
<HEADING LEVEL="5">Comparator interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus placebo</HEADING>
<P>Four trials used 50 mg to 75 mg diclofenac (<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>; <LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>), and one trial used ketoprofen versus placebo (<LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus opioids</HEADING>
<P>Three trials compared ketorolac (<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), and one trial compared flurbiprofen with opioids (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus spasmolytic drugs</HEADING>
<P>Two trials compared diclofenac (<LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>), one trial compared tenoxicam (<LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>), and one trial compared flurbiprofen with spasmolytic drugs (hyoscine butylbromide) (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The 12 trials randomised a total of 828 people (minimum 30 and maximum 324 per trial). Twenty-four per cent of the participants were males.The age of participants in the trials ranged from 18 to 86 years. All participants were admitted to the emergency department for acute biliary pain.</P>
<P>Age lower than 65 years represented an exclusion criteria in three trials (<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), and the presence of co-morbidities such as diabetes mellitus, cardiovascular, or respiratory diseases represented an exclusion criteria in one trial (<LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>). In the Henderson trial, the presence of renal insufficiency represented another exclusion criteria in addition to age (<LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Comparator interventions</HEADING>
<P>Five trials used placebo (<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>; <LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>; <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>), four trials used opioids (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), and four trials used spasmolytic drugs in the control group (<LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>). In one of the included trials, NSAIDs were compared with both opioids and spasmolytic drugs (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>).</P>
<P>We identified one ongoing trial entitled "Analgesic efficacy of intravenous ibuprofen in biliary colic" by searching ClinicalTrials.gov, which is currently recruiting participants (<LINK REF="STD-NCT02268955" TYPE="STUDY">NCT02268955</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-09-07 13:10:07 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>We excluded six studies for the following reasons (<LINK REF="STD-Thornell-1979" TYPE="STUDY">Thornell 1979</LINK>; <LINK REF="STD-Niinikoski-1984" TYPE="STUDY">Niinikoski 1984</LINK>; <LINK REF="STD-Kantor-1986" TYPE="STUDY">Kantor 1986</LINK>; <LINK REF="STD-Marsala-1986" TYPE="STUDY">Marsala 1986</LINK>: <LINK REF="STD-Chaudhary-1999" TYPE="STUDY">Chaudhary 1999</LINK>; <LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>): one study was not a randomised clinical trial (<LINK REF="STD-Thornell-1979" TYPE="STUDY">Thornell 1979</LINK>), one study compared two different types of NSAIDs (<LINK REF="STD-Niinikoski-1984" TYPE="STUDY">Niinikoski 1984</LINK>), one was a review (<LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>), one study compared two different modalities of sodium naproxen administration (intravenous versus intramascular) (<LINK REF="STD-Marsala-1986" TYPE="STUDY">Marsala 1986</LINK>), one used an association of NSAIDs administered together (<LINK REF="STD-Chaudhary-1999" TYPE="STUDY">Chaudhary 1999</LINK>), and one used NSAID for dental pain (<LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-09-08 12:23:56 +0200" MODIFIED_BY="[Empty name]">
<P>Overall, we judged all but one trial comparing NSAIDs versus placebo to be at low risk of bias (<LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2016-09-07 13:10:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We judged five trials as at low risk of bias (<LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), and the other seven as at unclear risk of bias for the domain allocation sequence generation (<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>; <LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>; <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>).</P>
<P>Allocation concealment was adequately performed in two trials (<LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), inadequately performed in one trial (<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>), and unclear in the remaining nine trials (<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>; <LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>; <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-09-08 12:23:56 +0200" MODIFIED_BY="[Empty name]">
<P>We considered nine trials as at low risk of bias (<LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>; <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), and three as at unclear risk of bias regarding both blinding of participants and personnel and blinding of outcome assessment (<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>). </P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-09-07 13:11:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Eleven trials were at low risk of bias (<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>; <LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>; <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), and one trial was at unclear risk of bias for incomplete outcome data (<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-09-07 13:11:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Seven trials were at low risk of bias (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>), and five trials were at unclear risk for selective outcome reporting (<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>; <LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>; <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-09-07 13:11:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We observed no risk of for-profit bias on the side of researchers, industries, or funding bodies, or any personal conflicts by the authors of the trial publication in any of the included trials.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-09-09 12:15:57 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>No participants in the included trials died.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lack of pain relief</HEADING>
<P>The definition of 'lack of pain relief' differed slightly in the included studies. However, it included:</P>
<UL>
<LI>the need for a rescue therapy after a given period (15 minutes, 30 minutes, 1 hour, 24 hours, etc.) following NSAIDs administration;</LI>
<LI>inadequately subjective pain relief within a given period following NSAIDs administration.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus placebo</HEADING>
<P>When compared with placebo, NSAIDs obtained a significantly lower proportion of participants without complete pain relief (risk ratio (RR) 0.27, 95% confidence interval (CI) 0.19 to 0.40; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Trial Sequential Analysis found that the required information size was 266 participants (see details in <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The cumulative number of participants enrolled in the trials included in this meta-analysis was 208, corresponding to 78% of the information size. The results of the Trial Sequential Analysis support the finding that NSAIDs are superior to placebo in relieving pain, as the cumulative Z-curve crossed both the conventional and the trial sequential monitoring boundary for benefit (during the third trial in 1985) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The Trial Sequential Analysis-adjusted CI was 0.17 to 0.43.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus opioids</HEADING>
<P>We found no difference when comparing NSAIDs to opioids (different doses) (ketorolac, three trials (<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>; <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>); flurbiprofen, one trial (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>)) (RR 0.98, 95% CI 0.47 to 2.07; I<SUP>2</SUP> = 52%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>Trial Sequential Analysis was performed considering an event rate in the control group of 18%, a relative risk reduction of 20%, risk of type I error of 5%, power of 80%, and diversity 88%. The required information size was 13,657 participants. The number of participants included in this meta-analysis was 459, corresponding to 3.4% of the information size. We did not calculate the Trial Sequential Analysis-adjusted CI due to little information (3.4%).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus spasmolytic drugs</HEADING>
<P>When compared with spasmolytic drugs, NSAIDs (diclofenac, two trials (<LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>); tenoxicam, one trial (<LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>); and flurbiprofen, one trial (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>)) showed a significantly lower proportion of participants without complete pain relief (RR 0.51, 95% CI 0.37 to 0.71; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Trial Sequential Analysis found that the required information size was 626 participants (see details in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The total number of participants included in this analysis was 190 (30% of the information size). The results of the Trial Sequential Analysis do not support the finding that NSAIDs are superior to spasmolytic drugs in relieving pain, as the cumulative Z-curve did not cross the trial sequential boundaries (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The Trial Sequential Analysis-adjusted CI was 0.27 to 0.98.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Cholelithiasis-related complications</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus placebo</HEADING>
<P>Three trials reported data on cholelithiasis-related complications (<LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>). When compared with placebo, NSAIDs showed no effect on complications (RR 0.66, 95% CI 0.38 to 1.15; I<SUP>2 </SUP>= 26%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Trial Sequential Analysis showed that the required information size was 1788 participants (see details in <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The cumulative number of participants enrolled in the trials included in this meta-analysis was 140, corresponding to 8% of the information size. The cumulative Z-curve did not cross the trial sequential monitoring boundaries. The Trial Sequential Analysis-adjusted CI was 0.07 to 6.19.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus opioids</HEADING>
<P>Only one trial comparing NSAIDs with opioids reported data on cholelithiasis-related complications (<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>), and found no difference in the occurrence of events between the two groups (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>As only one trial was included, we did not perform the Trial Sequential Analysis. However, we attempted to estimate the required information size (assuming a rate of events in the control group of 14%, a relative risk reduction of 20%, a risk of type I error of 5%, a power of 80%, and a diversity of 50%), which resulted in 8820 participants. We did not calculate the Trial Sequential Analysis-adjusted CI due to little information (0.3%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">NSAIDs versus spasmolytic drugs</HEADING>
<P>Two trials reported data on cholelithiasis-related complications (<LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>). When compared with spasmolytics, NSAIDs showed a significantly lower proportion of disease-related complications (RR 0.27, 95% CI 0.12 to 0.57; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>Trial Sequential Analysis showed that the required information size was 1800 participants (see details in <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The cumulative number of participants enrolled in the trials included in this meta-analysis was 104, corresponding to 6% of the information size. The results of the Trial Sequential Analysis do not support the finding of the conventional meta-analysis. The cumulative Z-curve did not cross the trial sequential monitoring boundaries (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The Trial Sequential Analysis-adjusted CI was 0.01 to 6.06.</P>
<P>No data were available from the trial reports concerning either the risk of bleeding after an operative intervention or after an ERCP procedure.</P>
<P>Major bleeding was defined as a reduction in the haemoglobin level of at least 20 grams per litre, transfusion of at least 2 units of blood, or symptomatic bleeding.</P>
<P>Life-threatening bleeding was a subcategory of major bleeding that consisted of fatal bleeding, symptomatic intracranial bleeding, bleeding with a decrease in the haemoglobin level of at least 50 grams per litre, or bleeding requiring transfusion of at least 4 units of blood or inotropic agents or necessitating surgery.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>None of the included trials assessed quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug-related complications and adverse events, expressed as the number of participants experiencing these events</HEADING>
<P>None of the 12 included trials reported severe adverse events. Seven out of the 12 trials assessed non-severe adverse events; in two out of the seven trials no adverse events were observed. In the trial by Camp and colleagues (<LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>), some mild adverse events were reported. Among the 30 participants on flurbiprofen, one participant had fever and one experienced anxiety; among the 25 participants on hyoscine butylbromide one had headache, one nausea, one dry mouth, and one tachycardia; and among the 29 participants on pentazocine, six had nausea, four vomiting, one dry mouth, and five dizziness. In the trial by Grossi and colleagues (<LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>), no participants on diclofenac or hyoscine butylbromide experienced adverse events. However, diclofenac and hyoscine butylbromide caused a significant decrease in systolic blood pressure. In the trial by Henderson and colleagues (<LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>), drowsiness was the most frequent adverse event, observed in 34.6% of the 175 participants treated with ketorolac and 42.1% of the 149 participants treated with pethidine. Nausea and dizziness were significantly more frequent in the pethidine group than in the ketorolac group (16.4% versus 6.8% and 17.9% versus 6.8%). In the trial by Olsen and colleagues (<LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK>), the proportion of participants experiencing nausea (24% versus 4%), vomiting (5% versus 0%), and rash (0% versus 4%) did not differ significantly between the ketorolac group and the butorphanol group, whereas the proportion of participants experiencing sedation (5% versus 36%) and dizziness (0% versus 28%) was significantly higher in the butorphanol group as compared to ketorolac group. In the trial by Lunstam and colleagues (<LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>), only significant decrease in systolic blood pressure was observed in both groups (diclofenac or placebo). In the trial by Magrini and colleagues (<LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>), blood pressure was moderately but significantly decreased in the two treatment groups (ketoprofen or lysine acetyl salicylate), while this was not observed in the placebo group.</P>
<P>Meta-analyses of the quantification of pain relief were not possible as the included trials used different scoring scales, and pain was assessed at different time points after the intervention. Also, the definition of the timespan to obtain pain relief was very heterogeneous among trials, preventing any possible comparison among patient groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quantification of pain relief</HEADING>
<P>In most of the included trials quantification of pain relief was assessed using different visual analogue scales (VAS), precluding any possible comparisons among trial participant groups.</P>
<P>
<LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK> assessed the severity of pain used a three-point scale (1 = no relief, 2 = partial relief, 3 = complete relief) every 5 minutes up to 25 minutes after drug injection. <LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK> used a similar approach, assessing pain intensity after 15 and 30 minutes after the drug injection. <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK> rated pain severity according to a four-point scale (0 = no effective, 1 = mildly effective, 2 = moderately effective, 3= completely effective) before and 30 minutes after injection of medication. In <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>, pain severity was graded on a four-point categorical scale (0 = no pain, 1 = mild, 2 = moderate, 3= severe), and mean VAS for the two treatment groups were compared after 30 minutes, 1 and 2 hours after drug injection. <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK> used a four-point semi-quantitative scale to quantify pain severity (0 = no pain, 1 = mild, 2 = moderate, 3 = severe), and the evolution of pain was checked every hour until 6 hours after drug injection. <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK> used a five-point scale (0 = no pain, 1 = mild, 2 = moderate, 3 = severe; 4 = very severe), but pain intensity was assessed at 15, 30, 60, and 120 minutes after drug injection. In <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>, response of pain to treatment was defined as no response (same or worse grade), improvement (amelioration of pain by at least one grade), or relief. The severity of pain was graded according to a four-point scale (0 = absent, 1 = mild, 2 = moderate, and 3 = severe requiring analgesia). Sequential assessment for response of pain to treatment was performed every 15 minutes for the first 120 minutes and every 60 minutes for the first 8 hours after drug administration. In <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>, a five-point categorical scale (0 = no pain, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe) was used and mean VAS recorded at 30 and 60 minutes after drug administration. In <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>, pain severity was recorded on a 10-point VAS and checked at 30 minutes, 1, 2, and 4 hours after drug injection. <LINK REF="STD-Olsen--2008" TYPE="STUDY">Olsen 2008</LINK> used a 10-point faces numerical pain scale (1 minimal pain, 10 maximal) and assessed pain intensity 15 and 30 minutes after drug administration. In <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>, the severity of pain was rated on an A-to-D scale (A = mild pain; D = intractable pain) every 10 to 15 minutes. <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK> assessed the intensity of pain at 30 and 60 minutes after medication injection using a 100-millimetre analogue chromatic scale (0 mm = no pain, 100 mm = unbearable pain). Differences in the scales used for rating pain were accounted for by multiplying by 10 for the 10-point scale, by 20 for the five-point scale, and by 25 for the four-point scale. We left unchanged scales in which pain was rated on a 100-millimetre analogue chromatic rating system (data synthesis or extraction).</P>
<P>In <LINK REF="STD-Broggini-1984" TYPE="STUDY">Broggini 1984</LINK>, mean pain intensity changed 25 minutes after the injection on the VAS, from 80 mm to 9 mm in the diclofenac group and from 85 mm to 86 mm in the placebo group.</P>
<P>
<LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK> observed that pain estimated on the VAS was reduced by 58% in the diclofenac group and 39% in the placebo group.</P>
<P>
<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK> observed that pain relief at 30 minutes was 3.8 ± 2.6 in the ketorolac group and 3.9 ± 2.5 in the pethidine group, a difference that was not statistically significant.</P>
<P>In <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>, no significant differences in mean VAS values were found between groups at two hours after drug injection (ketorolac versus pethidine).</P>
<P>In <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>, participants receiving ibuprofen showed significantly lower mean pain intensity VAS values compared to those receiving pentazocine or hyoscine butylbromide .</P>
<P>In <LINK REF="STD-Magrini-1985" TYPE="STUDY">Magrini 1985</LINK>, total pain score and VAS values were significantly lower at each time point in the ketoprofen group as compared to placebo.</P>
<P>In <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>, response of pain to treatment was defined as no response (same or worse grade), improvement (amelioration of pain by at least one grade), or relief. No data were available regarding pain quantification and its modification over time (<LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>).</P>
<P>In <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>, mean pain score in the tenoxicam group decreased from 2.75 ± 0.9 to 0.49 ± 0.51 at 30 minutes and to 0.58 ± 0.57 at 60 minutes; in the hyoscine butylbromide group pain decreased from 2.62 ± 1.0 to 0.57 ± 0.5 at 30 minutes and to 0.66 ± 0.5 at 60 minutes.</P>
<P>In <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>, at 2 hours from injection, pain severity in the diclofenac group decreased from 9.5 ± 0.54 to 0.62 ± 0.83, and in the hyoscine group it decreased from 9.6 ± 0.48 to 1.69 ± 1.0.</P>
<P>In <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>, severity of pain was rated on an A-to-D scale (A = mild pain; D = intractable pain) every 10 to 15 minutes. No data were available on the quantification of pain, but average response time lapse was shortest in the diclofenac group (15 minutes) as compared to placebo (35 minutes) and papaverine group (20 minutes).</P>
<P>
<LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK> observed the course of pain intensity over the 60 minutes after injection, showing that all three of the drugs studied were effective in relieving pain, however the diclofenac group showed a significantly higher reduction in mean pain score as compared to the glucagon and hyoscine butylbromide groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">The time needed to obtain pain relief</HEADING>
<P>Most of the included trials reported the time needed to obtain pain relief only as a descriptive variable. Most of the trials assessed participants at predefined time intervals, ranging from 25 minutes up to 3 hours (see data reported in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section and in the previous paragraph).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>It was not possible to conduct any of the planned subgroup analyses due to the low number of trials and the lack of data regarding the predefined variables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We planned no sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events reported in non-randomised studies</HEADING>
<P>Our search was primarily aimed at identifying randomised clinical trials. However, we retrieved from the searches several citations from quasi- or non-randomised studies. We searched for adverse events in these studies, but were unable to find any specific adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Publication bias</HEADING>
<P>It was not possible to create a funnel plot to assess publication bias as the number of trials in each of the four meta-analyses was less than 10.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">GRADE assessments</HEADING>
<P>We rated the quality of evidence for two of the primary outcomes, lack of pain relief and cholelithiasis-related complications, in the 'Summary of findings' tables. We performed the assessment of these outcomes for the three analysed comparisons in separate: NSAIDs versus placebo; NSAIDs versus opioids; and NSAIDs versus spasmolytic drugs. For the comparison NSAIDs versus placebo, we graded the overall quality low for 'lack of pain relief' and very low for 'cholelithiasis-related complications' (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>); for NSAIDs versus opioids, we graded the overall quality very low for both 'lack of pain relief' and 'cholelithiasis-related complications' (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>); and for NSAIDs versus spasmolytic drugs, we graded the overall quality low for both 'lack of pain relief' and 'cholelithiasis-related complications' (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-09-09 12:29:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2016-09-09 12:29:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Twelve randomised clinical trials assessed the use of NSAIDs in people attending emergency departments with symptoms of biliary colic. Our traditional meta-analysis showed NSAIDs to be effective in relieving pain by significantly reducing the number of participants without complete pain relief in comparison to placebo or spasmolytic drugs. However, Trial Sequential Analysis confirmed only the result obtained when comparing NSAIDs with placebo. The trials comparing NSAIDs and opioids failed to demonstrate a significant difference; however, present data are not able to definitively support equivalence in pain relief between these two classes of drugs. Moreover, NSAIDs significantly reduced the proportion of short-term complications such as acute cholecystitis, jaundice, cholangitis, and acute pancreatitis when compared with spasmolytics, but not when compared with placebo. This effect may be due either to a beneficial effect of NSAIDs or to a harmful effect of spasmolytic drugs, however the latter could not be currently determined.</P>
<P>Five trials tested diclofenac 50 mg to 75 mg intramuscularly (i.m.) and ketoprofen 200 mg intravenously (i.v.) against placebo (saline) with consistent results demonstrating a superior analgesic efficacy of these two NSAIDs. This result was confirmed by the Trial Sequential Analysis. However, the comparison between NSAIDs and other commonly used drugs (spasmolytic and opioid) seems more relevant.</P>
<P>Hyoscine butylbromide (also known as scopolamine) is an anticholinergic drug, commonly used because of its presumed spasmolytic activity. We found four randomised clinical trials comparing NSAIDs and hyoscine butylbromide that consistently and significantly demonstrated a more effective pain relief with NSAIDs (diclofenac 75 mg i.m., tenoxicam 20 mg i.v., and flurbiprofen 150 mg i.m.) than the spasmolytic drugs (hyoscine butylbromide 20 mg i.v. or i.m., hyoscine butylbromide 20 mg i.m). In one trial, glucagon (1 mg i.m.) was as effective as diclofenac (75 mg i.m) for obtaining pain relief (<LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>). However, glucagon is no longer used due to its adverse effects. Due to their well-known analgesic effect, pethidine and pentazocine are commonly used, in particular because they prevent the sphincter of Oddi spasm associated with use of the other opioids. However, the Trial Sequential Analysis did not support the finding of the conventional meta-analysis, suggesting that firm evidence has not yet been reached.</P>
<P>Only four trials compared NSAIDs versus opioids (two with pethidine, one with pentazocine, and one with butorphanol) including about 242 and 217 participants in each group. The results for this comparison showed significant statistical heterogeneity, and no difference in the analgesic effect was observed between the two drugs. A possible explanation for the inconsistency of data could be related to the different drugs used, route of administration, and time of pain assessment. In particular, the largest trial by Henderson (<LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>) used pethidine 50 mg intravenously and assessed pain after 1 hour, whereas the other three smaller trials used pentazocine or pethidine intramuscularly and assessed pain earlier, at 30 minutes. The present data do not allow us to reject the null hypothesis, as they are underpowered. Also in this analysis, the Trial Sequential Analysis did not support the result of the meta-analysis, implying that firm evidence was not reached.</P>
<P>The percentage of participants with biliary colic who developed cholelithiasis-related complications such as cholecystitis, or less frequently choledocholithiasis, cholangitis, or gallstone pancreatitis, varied. Our results indicate that NSAIDs were not able to reduce the rate of short-term complications of biliary colic in comparison with placebo; we observed a reduction in the rate of cholelithiasis-related complications in comparison with spasmolytic drugs, even if this result was not confirmed by Trial Sequential Analysis.</P>
<P>The interpretation of our findings regarding cholelithiasis-related complications is difficult and should be considered with caution. In fact, the studies included in the two analyses (NSAIDs versus placebo and NSAIDs versus spasmolytic drugs) are very different. For example, there was a higher rate of complications in the treatment arm of trials included in the former analysis (29%) as compared to the latter analysis (11%). This is likely a consequence of different participant selection with varying disease severity and probably for different definitions of complications. In only one trial, comparing NSAIDs versus placebo, were cholelithiasis-related complications assessed and separately reported according to clearly predefined criteria (<LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>). In two other trials, comparing NSAIDs versus placebo (<LINK REF="STD-Lundstam--1985" TYPE="STUDY">Lundstam 1985</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>), and in two trials comparing NSAIDs versus spasmolytics (<LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>), only the rate of clinically evident cholecystitis was recorded. In addition, when exclusion criteria were stricter in some of the trials (<LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>), incidences of complications were lower. People with diabetes or other systemic comorbidities and people older than 65 years were excluded from all trials, apart from <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>. These people can be regarded as a subgroup in which complications related to cholelithiasis are more frequent and severe (<LINK REF="REF-Kimura-2007" TYPE="REFERENCE">Kimura 2007</LINK>).</P>
<P>The above concept applies also for adverse events related to NSAIDs. In most of the included trials, data collection about adverse drug effects was neither planned nor reported. These limitations prevent clear and definitive assessment of the benefits and harms of the use of NSAIDs just in the subgroup of participants with higher risk of severe complications, particularly in comparison to pethidine, which shows at least similar analgesic activity (<LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Henderson-2002" TYPE="STUDY">Henderson 2002</LINK>).</P>
<P>There was no clear difference in the reported number or severity of adverse effects between the different types of NSAIDs in the trials included in this review. Several articles have reported on the adverse effects of NSAIDs, especially gastrointestinal events. Adverse effects that were more frequently reported in the trials presented in this review included nausea, dry mouth, abdominal pain, diarrhoea, oedema, decrease in systolic blood pressure, rash, dizziness, headache, tiredness, fever, and anxiety.</P>
<P>The authors of the included trials considered most adverse effects to be mild to moderate. However, as the sample sizes of most of the studies were relatively small, no clear conclusion can be drawn regarding the risks for gastrointestinal and other adverse effects of NSAIDs.</P>
<P>Regarding the possible onset of cardiovascular adverse effects, apart from a transitory decrease in systolic blood pressure, these were not reported in the trials included in our present review. However, it must be noted that cardiovascular adverse events are more common with the use of cyclooxygenase&#8209;2 (COX-2) inhibitor drugs than with classical NSAIDs, and that the use of NSAIDs can be considered to be relatively safe when prescribed at the most effective dose and for the shortest period of time (<LINK REF="REF-Aminoshariae-2016" TYPE="REFERENCE">Aminoshariae 2016</LINK>). Indeed, in the trials included in the present systematic review, NSAIDs were used for a very short period of time, and in all cases for less than 10 days.</P>
<P>None of the included trials reported data on the possible association between NSAIDs use and increased risk of bleeding after surgical or endoscopic procedures for cholelithiasis-related complications. In a recent meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis, the risk of bleeding seems not to be increased (<LINK REF="REF-Elmunzer-2008" TYPE="REFERENCE">Elmunzer 2008</LINK>). Interestingly, NSAIDs are effective in the prevention of post-ERCP pancreatitis, and this may further support our findings of a low proportion of cholelithiasis-related complications, probably related to inhibition of prostaglandin, phospholipase A2, and neutrophil-endothelial interactions, all of which are involved in their pathogenesis (<LINK REF="REF-Zheng-2008" TYPE="REFERENCE">Zheng 2008</LINK>).</P>
<P>We also found one ongoing randomised clinical trial that aims to assess the analgesic efficacy of intravenous ibuprofen in biliary colic.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-09-08 16:39:40 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This systematic review examined the evidence from 12 randomised trials comparing NSAIDs versus no intervention, placebo, or other drugs in people attending emergency departments with symptoms of biliary colic. These trials included all people presenting with biliary colic according to the definitions and diagnostic work-up in the individual trials.</P>
<P>All trials reported on the primary outcomes of mortality, (lack of) complete pain relief, and number of participants with cholelithiasis-related complications, whereas in most of the included trials no data were available regarding drug-related complications and adverse events, and most of the remaining secondary outcomes such as risk of bleeding after surgical or endoscopic procedures, quality of life, quantification of pain relief, and time to obtain pain relief.</P>
<P>In addition, when exclusion criteria were stricter in some of the trials (<LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>), incidences of complications were lower. People with diabetes or other systemic comorbidities or who were older than 65 years were excluded from all trials, apart from <LINK REF="STD-Akriviadis-1997" TYPE="STUDY">Akriviadis 1997</LINK>. These people can be regarded as a subgroup in which complications related to cholelithiasis are more frequent and severe (<LINK REF="REF-Kimura-2007" TYPE="REFERENCE">Kimura 2007</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-09-08 13:16:19 +0200" MODIFIED_BY="[Empty name]">
<P>We conducted our review following the recommendations of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> and the Cochrane Hepato-Biliary Group (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Gluud-2016" TYPE="REFERENCE">Gluud 2016</LINK>). The findings of our review and the quality of the evidence are affected by the quality of the primary trials included in the review. We found only one trial to be at low risk of bias for all the quality domains considered. We considered most of the trials to be at unclear risk of bias for at least two quality domains, and only one trial to be at high risk of bias for at least one quality domain. In particular, we more frequently observed risk of bias for the random sequence generation and allocation concealment domains, both of which reflect the presence of a selection bias.</P>
<P>However, for trials classified as at unclear risk of bias, we cannot exclude the presence of high risk of bias.</P>
<P>We also performed Trial Sequential Analysis to deal with the risks of random errors and to prevent premature declaration of superiority of NSAIDs (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). According to these analyses, systematic errors may still influence the results of a number of comparisons in our review.</P>
<P>Regarding GRADE assessments, we rated none of the trials as providing strong evidence, primarily because of the presence of risk of bias, the required information size was not reached, and imprecision of pooled estimates.<BR/>
</P>
<P>Overall, we did not observe relevant heterogeneity among the studies apart from exclusion criteria differing in some of them, for example the exclusion of participants older than 65 years or of those with comorbidities such as diabetes, or a different definition of complications.</P>
<P>The presence of a possible publication bias cannot be excluded as a formal analysis was prevented by the small number of studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-09-07 13:17:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We attempted to minimise the risk of bias in the review process by strictly following Cochrane's methodology during the preparation of our review.</P>
<P>We performed an exhaustive bibliographic search, and two review authors extracted data independently. Although the search strategy was very sensitive, due to the low number of included trials we could not test for funnel plot asymmetry to assess the risk of publication bias. This is a clear limitation of our review.</P>
<P>The quality of the primary trials included in our review is, as usual, a limiting factor for the strength of the evidence of our results.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-09-07 13:18:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>With respect to the two non-Cochrane systematic reviews already published (<LINK REF="REF-Basurto-Ona-2008" TYPE="REFERENCE">Basurto Ona 2008</LINK>; <LINK REF="REF-Colli-2012" TYPE="REFERENCE">Colli 2012</LINK>), some main differences should be underlined.</P>
<P>The earliest-dated review is a Spanish review that does not compare NSAIDs versus placebo or other drugs for biliary colic in people with cholelithiasis (<LINK REF="REF-Basurto-Ona-2008" TYPE="REFERENCE">Basurto Ona 2008</LINK>). The authors concluded that NSAIDs are the first drugs that should be used in people with uncomplicated biliary colic, as they found a significantly higher analgesic effect and a better prognosis (lower rate of progression to acute cholecystitis) for NSAIDs as compared to 'other drugs', which, differing from the present review, they considered to be a heterogeneous group of drugs. <LINK REF="REF-Basurto-Ona-2008" TYPE="REFERENCE">Basurto Ona 2008</LINK> included only seven randomised clinical trials that enrolled 349 participants (<LINK REF="STD-Niinikoski-1984" TYPE="STUDY">Niinikoski 1984</LINK>; <LINK REF="STD-Grossi-1986" TYPE="STUDY">Grossi 1986</LINK>; <LINK REF="STD-Camp-1992" TYPE="STUDY">Camp 1992</LINK>; <LINK REF="STD-Al-Waili-1998" TYPE="STUDY">Al Waili 1998</LINK>; <LINK REF="STD-Dula-2001" TYPE="STUDY">Dula 2001</LINK>; <LINK REF="STD-Goldman-2001" TYPE="STUDY">Goldman 2001</LINK>; <LINK REF="STD-Kumar-2004" TYPE="STUDY">Kumar 2004</LINK>). We included all of these studies, apart from one that we excluded as it compares two NSAIDs (indomethacin 50 mg versus metamizole 2.5 g) (<LINK REF="STD-Niinikoski-1984" TYPE="STUDY">Niinikoski 1984</LINK>), in our own review.</P>
<P>Our own group published the other non-Cochrane review (<LINK REF="REF-Colli-2012" TYPE="REFERENCE">Colli 2012</LINK>). In this review, we did not rate the overall evidence and did not perform a Trial Sequential Analysis to calculate the cumulative sample size of the meta-analysis (information size), thus overestimating the efficacy of NSAIDs in reducing biliary colic complications.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-09-07 13:18:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2016-09-07 13:18:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Our results indicate that NSAIDs control pain better than placebo and spasmolytic drugs in people with biliary colic. However, only one randomised clinical trial was at low risk of bias.</P>
<P>We found limited evidence that NSAIDs reduce cholelithiasis-related complications. Regarding the reduced risk of cholelithiasis-related complications observed for NSAIDs versus spasmolytic drugs, the evidence is provided by only two trials including 104 participants. In addition, it is unclear whether this finding is related to the beneficial effect of NSAIDs or to a harmful effect of spasmolytics.</P>
<P>Furthermore, regarding the presence of complications, a limitation of the present systematic review is that its generalisability is low as most of the randomised clinical trials did not include elderly people or people with co-morbidities, or both, who are more prone to complication as compared to other included participants.</P>
<P>None of the trials provided information on quality of life, and information on adverse events remains unclear.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-09-07 13:18:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We need more evidence with appropriately sized randomised clinical trials at low risk of bias before we can draw any firm conclusions on the effect of NSAIDs in pain control for people with biliary colic.</P>
<P>The lack of data regarding people with a wider spectrum of age or with co-morbidities (e.g. diabetes, etc.), or both, actually representing the subgroup with a higher proportion of severe gallstone-related complications, makes the conclusions of this review not completely generalisable, indicating a need for new trials with less stringent inclusion criteria.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-09-07 13:18:22 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We are indebted to Sarah Klingenberg and Giovanna Pistotti for their precious help in revising the search strategy terms.<BR/>
<BR/>Peer reviewers: Jessica Vaughan, UK; Malgorzata Bala, Poland.<BR/>Contact editors: Saboor A. Khan, UK; Frederik Keus, the Netherlands; Christian Gluud, Denmark.</P>
<P>Cochrane Review Group funding acknowledgement: the Danish State is the largest single funder of the Cochrane Hepato-Biliary Group through its investment in the Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Denmark. Disclaimer: The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the Danish State or the Copenhagen Trial Unit.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-08-16 14:46:59 +0200" MODIFIED_BY="[Empty name]">
<P>Mirella Fraquelli: none known.<BR/>Giovanni Casazza: none known.<BR/>Dario Conte: none known.<BR/>Agostino Colli: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-04-20 18:08:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mirella Fraquelli: conception and design, drafting, and final revision of the review.<BR/>Giovanni Casazza: Trial Sequential Analysis and drafting of the review.<BR/>Dario Conte: conception and design, and drafting of the review.<BR/>Agostino Colli: conception and design, and drafting of the review.</P>
<P>All authors approved the current review version for publication.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-09-07 13:18:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The main outcome as stated in the protocol was initially pain relief (<LINK REF="REF-Colli-2007" TYPE="REFERENCE">Colli 2007</LINK>). One of the peer reviewers suggested changing the outcome into the proportion of participants who had 'lack of pain relief', and we agreed to this. We thus divided outcomes into primary (1. mortality and 2. lack of pain relief) and secondary (1. number of people with cholelithiasis-related complications (e.g. acute cholecystitis, acute pancreatitis, jaundice, cholangitis; number of people manifesting bleeding from operative intervention or ERCP less than 9, or both; 2. quality of life; 3. drug-related complications and adverse events, expressed as the number of people experiencing any event (e.g. gastrointestinal bleeding, cutaneous rash, renal function impairment, cardiovascular events, and any other described in the trials); 4. quantification of pain relief in which intensity of pain was rated in the trials on a quantitative scale in the following way: the difference of pain intensity after 30 or 60 minutes from treatment compared with pain intensity at enrolment. Differences in the scale used for rating pain were accounted for by multiplying by 10 for the 10-point scale, by 20 for the five-point scale, and by 25 for the four-point scale. We left unchanged scales in which pain was rated on a 100-millimetre analogue chromatic rating system (data synthesis or extraction); 5. the time needed to obtain pain relief: complete pain relief or any small amount of pain relief (as defined by the different trials).</P>
<P>We have added information about Trial Sequential Analysis at the review stage, as at the time of the protocol preparation it was not completely developed.</P>
<P>We have added the incomplete outcome data 'Risk of bias' domain to the 'Risk of bias' assessment.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-09-09 12:32:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2016-09-09 12:03:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<INCLUDED_STUDIES MODIFIED="2016-09-07 06:50:09 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akriviadis-1997" MODIFIED="2016-09-07 06:50:09 +0200" MODIFIED_BY="[Empty name]" NAME="Akriviadis 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-09-07 06:50:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akriviadis EA, Hatzigavriel M, Kapnias D, Kirimlidis J, Markantas A, Garyfallos A</AU>
<TI>Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>113</VL>
<PG>225-31</PG>
<IDENTIFIERS MODIFIED="2016-09-07 06:50:09 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379953"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-09-01 13:25:14 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379952"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al-Waili-1998" MODIFIED="2015-02-02 12:43:56 +0100" MODIFIED_BY="[Empty name]" NAME="Al Waili 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-02-02 12:43:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Waili N, Saloom KY</AU>
<TI>The analgesic effect of intravenous tenoxicam in symptomatic treatment of biliary colic: a comparison with hyoscine N-butylbromide</TI>
<SO>European Journal of Medical Research</SO>
<YR>1998</YR>
<VL>3</VL>
<PG>475-9</PG>
<IDENTIFIERS MODIFIED="2009-09-01 13:25:38 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379955"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379954"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Broggini-1984" MODIFIED="2015-02-02 14:06:32 +0100" MODIFIED_BY="[Empty name]" NAME="Broggini 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-02-02 14:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broggini M, Corbetta E, Grossi E, Borghi C</AU>
<TI>Diclofenac sodium in biliary colic: a double blind trial</TI>
<SO>British Medical Journal (Clinical Research Ed.)</SO>
<YR>1984</YR>
<VL>288</VL>
<PG>1042</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379957"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-09-01 13:25:54 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379956"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camp-1992" MODIFIED="2016-09-07 06:48:02 +0200" MODIFIED_BY="[Empty name]" NAME="Camp 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-09-07 06:48:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camp Herrero J, Artigas Raventos V, Millà Santos J, Allende Honorato L, Dominguez Granados R, Moreno Carretero E</AU>
<TI>Efficacy of injectable flurbiprofen in the symptomatic treatment of biliary colic</TI>
<TO>Eficacia del flurbiprofeno inyectable en el tratamiento sintomatico del colico biliar</TO>
<SO>Medicina Clinica</SO>
<YR>1992</YR>
<VL>98</VL>
<PG>212-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379959"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379958"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dula-2001" MODIFIED="2015-02-02 14:08:33 +0100" MODIFIED_BY="[Empty name]" NAME="Dula 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-02-02 14:08:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dula DJ, Anderson R, Wood GC</AU>
<TI>A prospective study comparing i.m. ketorolac with i.m. meperidine in the treatment of acute biliary colic</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>2</NO>
<PG>121-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379961"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379960"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldman-2001" MODIFIED="2015-02-02 14:08:46 +0100" MODIFIED_BY="[Empty name]" NAME="Goldman 2001" YEAR="1989">
<REFERENCE MODIFIED="2015-02-02 14:08:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldman G, Kahn PJ, Alon R, Wiznitzer T</AU>
<TI>Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1989</YR>
<VL>34</VL>
<NO>6</NO>
<PG>809-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379963"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379962"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grossi-1986" MODIFIED="2015-02-02 14:10:51 +0100" MODIFIED_BY="[Empty name]" NAME="Grossi 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-02-02 14:10:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grossi E, Broggini M, Quaranta M, Balestrino E</AU>
<TI>Different pharmacological approaches to the treatment of acute biliary colic</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1986</YR>
<VL>40</VL>
<PG>876-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379965"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379964"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-2002" MODIFIED="2015-02-02 14:23:15 +0100" MODIFIED_BY="[Empty name]" NAME="Henderson 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-02 14:23:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson SO, Swadron S, Newton E</AU>
<TI>Comparison of intravenous ketorolac and meperidine in the treatment of biliary colic</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>3</NO>
<PG>237-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379967"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379966"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-2004" MODIFIED="2015-02-02 14:23:39 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-02-02 14:23:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Deed JS, Bhasin B, Kumar A, Thomas S</AU>
<TI>Comparison of the effect of diclofenac with hyoscine-N-butylbromide in the symptomatic treatment of acute biliary colic</TI>
<SO>Australian and New Zealand Journal of Surgery</SO>
<YR>2004</YR>
<VL>371</VL>
<PG>435-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379969"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379968"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundstam--1985" MODIFIED="2016-09-07 06:50:00 +0200" MODIFIED_BY="[Empty name]" NAME="Lundstam  1985" YEAR="1985">
<REFERENCE MODIFIED="2015-02-02 14:23:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundstam S, Ivarsson L, Lindblad L, Kral JG</AU>
<TI>Treatment of biliary pain by prostaglandin synthethase inhibition with diclofenac sodium</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>435-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379971"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379970"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magrini-1985" MODIFIED="2015-02-02 14:24:16 +0100" MODIFIED_BY="[Empty name]" NAME="Magrini 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-02-02 14:24:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Magrini M, Rivolta G, Movilia PG, Moretti MP, Liverta C, Bruni G</AU>
<TI>Successful treatment of biliary colic with intravenous ketoprofen or lysine acetylsalicylate</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1985</YR>
<VL>9</VL>
<NO>7</NO>
<PG>454-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379973"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379972"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen--2008" MODIFIED="2016-08-19 12:10:01 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Olsen  2008" YEAR="2008">
<REFERENCE MODIFIED="2016-06-20 15:03:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen JC, McGrath NA, Schwarz DG, Cutcliffe BJ, Stern JL</AU>
<TI>A double-blind randomized clinical trial evaluating the analgesic efficacy of ketorolac versus butorphanol for patients with suspected biliary colic in the emergency department</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>718-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379975"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-19 12:10:01 +0200" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379974"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-09-07 14:52:53 +0200" MODIFIED_BY="Sarah  Klingenberg">
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2002" MODIFIED="2016-08-19 12:10:07 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Chang 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-02 14:24:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang DJ, Desjardins PJ, Chen E, Polis AB, McAvoy M, Mockoviak SH, et al</AU>
<TI>Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<PG>490-503</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379977"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-19 12:10:07 +0200" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379976"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhary-1999" MODIFIED="2016-09-07 14:52:53 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Chaudhary 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-09-07 14:52:53 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhary A, Gupta RL</AU>
<TI>Double blind, randomised, parallel, prospective, comparative, clinical evaluation of a combination of antispasmodic analgesic Diclofenac + Pitofenone + Fenpiverinium (Manyana) vs Analgin + Pitofenone + Fenpiverinium (Baralgan) in biliary, ureteric and intestinal colic</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>1999</YR>
<VL>97</VL>
<PG>244-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379979"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379978"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kantor-1986" MODIFIED="2015-02-02 14:28:25 +0100" MODIFIED_BY="[Empty name]" NAME="Kantor 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-02-02 14:26:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kantor TG</AU>
<TI>Use of diclofenac in analgesia</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<PG>64-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379981"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379980"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marsala-1986" MODIFIED="2015-02-02 14:28:33 +0100" MODIFIED_BY="[Empty name]" NAME="Marsala 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-02-02 14:26:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marsala F, Cavrini P, Bufalino L, Gardini F</AU>
<TI>Treatment of acute pain of ureteral and biliary colic with naproxen sodium administered by the parenteral route</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1986</YR>
<VL>6</VL>
<PG>495-500</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379983"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379982"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niinikoski-1984" MODIFIED="2016-09-07 06:54:58 +0200" MODIFIED_BY="[Empty name]" NAME="Niinikoski 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-02-02 14:27:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niinikoski J, Nelimarkka O, Pekkola P</AU>
<TI>Intravenous indomethacin in biliary pain. A clinical investigation with metamizole as the control</TI>
<SO>Annales Chirurgiae et Gynaecologiae</SO>
<YR>1984</YR>
<VL>73</VL>
<PG>69-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379985"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379984"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thornell-1979" MODIFIED="2016-08-19 12:10:17 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Thornell 1979" YEAR="1991">
<REFERENCE MODIFIED="2015-02-02 14:27:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornell E, Jansson R, Kral JG, Svanvik J</AU>
<TI>Inhibition of prostaglandin synthesis as a treatment for biliary pain</TI>
<SO>Lancet</SO>
<YR>1979</YR>
<VL>1</VL>
<PG>584</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379987"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-19 12:10:17 +0200" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379986"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2016-09-09 12:03:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02268955" MODIFIED="2016-09-09 12:03:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="NCT02268955" YEAR="2016">
<REFERENCE MODIFIED="2016-09-08 14:02:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT02268955</AU>
<TI>Assessment of the analgesic efficacy of intravenous ibuprofen in biliary colic</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02268955</SO>
<YR>(accessed October 16, 2014)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4379989"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4379988"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-09-09 13:29:00 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2016-09-09 13:29:00 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Aminoshariae-2016" MODIFIED="2016-07-21 14:15:41 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Aminoshariae 2016" TYPE="JOURNAL_ARTICLE">
<AU>Aminoshariae A, Kulild JC, Donaldson M</AU>
<TI>Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects: An updated systematic review</TI>
<SO>Journal of the American Dental Association (Edizione Italiana)</SO>
<YR>2016</YR>
<VL>147</VL>
<PG>98-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Angelico-1997" MODIFIED="2016-04-20 10:19:52 +0200" MODIFIED_BY="[Empty name]" NAME="Angelico 1997" TYPE="JOURNAL_ARTICLE">
<AU>Angelico F, Del Ben M, Barbato A, Conti R, Urbinati G</AU>
<TI>Ten-year incidence and natural history of gallstone disease in a rural population of women in central Italy. The Rome group for the epidemiology and prevention of cholelitiasis (GREPCO)</TI>
<SO>Italian Journal of Gastroenterology and Hepatology</SO>
<YR>1997</YR>
<VL>29</VL>
<PG>249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Attili-1995" NAME="Attili 1995" TYPE="JOURNAL_ARTICLE">
<AU>Attili AF, De Sanctis A, Capri R, Repice AM, Maselli S</AU>
<TI>The natural history of gallstones: the GREPCO experience. The GREPCO Group</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>3</NO>
<PG>655-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2015-07-24 11:38:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21208779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Basurto-Ona-2008" MODIFIED="2009-09-03 19:26:59 +0200" MODIFIED_BY="[Empty name]" NAME="Basurto Ona 2008" TYPE="JOURNAL_ARTICLE">
<AU>Basurto Ona X, Robles Perea L</AU>
<TI>Antinflammatory drugs for biliary colics: a systematic revision and meta-analysis of clinical trials</TI>
<TO>Antinflammatorios para el colico biliar: revision sistematica y metanalisis de ensayos clinicos</TO>
<SO>Gastroenterologia y Hepatologia</SO>
<YR>2008</YR>
<VL>31</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-1998" MODIFIED="2015-02-02 14:29:46 +0100" MODIFIED_BY="[Empty name]" NAME="Brooks 1998" TYPE="JOURNAL_ARTICLE">
<AU>Brooks P</AU>
<TI>Use and benefits of nonsteroidal anti-inflammatory drugs</TI>
<SO>American Journal of Medicine</SO>
<YR>1998</YR>
<VL>104</VL>
<PG>9S-13S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Colli-2012" MODIFIED="2016-07-21 14:17:03 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Colli 2012" TYPE="JOURNAL_ARTICLE">
<AU>Colli A, Conte D, Della Valle S, Sciola V, Fraquelli M</AU>
<TI>Meta-analysis: nonsteroidal anti-inflammatory drugs in biliary colic</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2012</YR>
<VL>35</VL>
<PG>1370-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2016-07-21 14:17:08 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2015-02-02 14:31:32 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elmunzer-2008" MODIFIED="2015-02-02 14:35:07 +0100" MODIFIED_BY="[Empty name]" NAME="Elmunzer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD</AU>
<TI>A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis</TI>
<SO>Gut</SO>
<YR>2008</YR>
<VL>57</VL>
<PG>1262-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-1993" MODIFIED="2016-07-21 14:17:32 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Friedman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Friedman GD</AU>
<TI>Natural history of asymptomatic and symptomatic gallstones</TI>
<SO>American Journal of Surgery</SO>
<YR>1993</YR>
<VL>165</VL>
<PG>399-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2016" MODIFIED="2016-09-09 13:29:00 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Gluud 2016" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL</AU>
<TI>Cochrane Hepato-Biliary Group</TI>
<SO>About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 6. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldman-1989" MODIFIED="2015-02-02 14:42:53 +0100" MODIFIED_BY="[Empty name]" NAME="Goldman 1989" TYPE="JOURNAL_ARTICLE">
<AU>Goldman G, Kahn PJ, Alon R, Wiznitzer T</AU>
<TI>Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1989</YR>
<VL>34</VL>
<PG>809-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grepco-I-1988" MODIFIED="2016-07-21 14:18:41 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Grepco I 1988" TYPE="JOURNAL_ARTICLE">
<TI>The epidemiology of gallstone disease in Rome, Italy. Part I. Prevalence data in men. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO)</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1988</YR>
<VL>8</VL>
<PG>904-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grepco-II-1988" MODIFIED="2016-07-21 14:18:47 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Grepco II 1988" TYPE="JOURNAL_ARTICLE">
<TI>The epidemiology of gallstone disease in Rome, Italy. Part II. Factors associated with the disease. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO)</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1988</YR>
<VL>8</VL>
<PG>907-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-07-24 11:38:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Vist GE, Kunz R, Falck Y, Alonso CP, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2016-09-07 14:53:17 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21195583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2015-07-24 11:38:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al</AU>
<TI>GRADE guidelines: 2. Framing the question and deciding on important outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21194891"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2016-09-07 14:53:29 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21247734"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2016-09-07 14:53:38 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence - publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2016-09-07 14:53:50 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21839614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2016-09-07 14:54:00 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21803546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011f" MODIFIED="2016-09-07 14:54:10 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2011f" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence - indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011g" MODIFIED="2015-07-24 11:38:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011g" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802902"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013" MODIFIED="2015-07-24 11:38:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2013" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>151-7</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="22542023"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013a" MODIFIED="2016-09-07 14:54:17 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al</AU>
<TI>GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>158-72</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="22609141"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013b" MODIFIED="2016-09-07 14:54:28 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al</AU>
<TI>GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>173-83</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="23116689"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013c" MODIFIED="2016-09-07 15:05:01 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2013c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Andrews J, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al</AU>
<TI>GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>7</NO>
<PG>719-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-09-07 14:55:40 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2015-07-24 11:37:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen J, Wetterslev J, Winkel P, Lange T, Gluud C</AU>
<TI>Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2001" MODIFIED="2016-07-21 14:19:27 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Johnson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Johnson CD</AU>
<TI>ABC of the upper gastrointestinal tract. Upper abdominal pain: gallbladder</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>316-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kimura-2007" MODIFIED="2016-09-07 14:56:13 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Kimura 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kimura Y, Takada T, Kawarada Y, Nimura Y, Hirata K, Sekimoto M, et al</AU>
<TI>Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines</TI>
<SO>Journal of Hepato-Biliary-Pancreatic Surgery</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>15-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2015-02-02 14:46:13 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2016-09-07 07:21:07 +0200" MODIFIED_BY="[Empty name]" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2016-09-07 07:21:07 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-09-07 07:21:07 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2016-09-07 14:56:28 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook D, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morgan-1999" MODIFIED="2015-02-02 14:46:37 +0100" MODIFIED_BY="[Empty name]" NAME="Morgan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Morgan G</AU>
<TI>Beneficial effects of NSAIDs in the gastrointestinal tract</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>1999</YR>
<VL>11</VL>
<PG>393-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mustafa-2013" MODIFIED="2015-07-24 11:39:17 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Mustafa 2013" TYPE="JOURNAL_ARTICLE">
<AU>Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al</AU>
<TI>The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>7</NO>
<PG>736-42; quiz 742.e1-5</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="23623694"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-10-21 05:57:16 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, Cochrane</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2015-02-02 14:47:46 +0100" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012" MODIFIED="2015-02-02 10:54:17 +0100" MODIFIED_BY="[Empty name]" NAME="Savovi&#263; 2012" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012a" MODIFIED="2015-02-02 10:54:17 +0100" MODIFIED_BY="[Empty name]" NAME="Savovi&#263; 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2015-02-02 14:48:16 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmer I, Hayes RS, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions and methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2016-09-07 14:56:43 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA)</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 2 February 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornell-1985" MODIFIED="2015-02-02 14:49:15 +0100" MODIFIED_BY="[Empty name]" NAME="Thornell 1985" TYPE="JOURNAL_ARTICLE">
<AU>Thornell E, Jansson R, Svanvik J</AU>
<TI>Indomethacin reduces raised intraluminal gallbladder pressure in acute cholecystitis</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1985</YR>
<VL>151</VL>
<PG>261-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2015-10-21 14:33:46 +0200" MODIFIED_BY="[Empty name]" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<TI>TSA - Trial Sequential Analysis</TI>
<YR>2011</YR>
<EN>0.9 Beta</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<MD>www.ctu.dk/tsa/downloads.aspx</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2014-06-27 11:42:40 +0200" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2015-02-02 14:52:10 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2015-02-02 10:54:17 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zheng-2008" MODIFIED="2015-02-02 14:52:27 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 2008" TYPE="JOURNAL_ARTICLE">
<AU>Zheng MH, Xia HH, Chen YP</AU>
<TI>Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis</TI>
<SO>Gut</SO>
<YR>2008</YR>
<VL>57</VL>
<PG>1262-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-09-07 14:57:28 +0200" MODIFIED_BY="Sarah  Klingenberg">
<REFERENCE ID="REF-Colli-2007" MODIFIED="2016-09-07 14:57:28 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Colli 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Colli A, Conte D, Sciola V, Fraquelli M</AU>
<TI>Non-steroid anti-inflammatory drugs for biliary cholics</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-02-02 14:55:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-02-02 14:55:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006390"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-09-09 12:27:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-09-09 12:26:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-09-09 11:54:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Akriviadis-1997">
<CHAR_METHODS MODIFIED="2016-09-07 13:18:36 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:18:36 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>People with right upper quadrant or epigastric pain seen in a Greek emergency department.</P>
<P>The presence of gallstones was documented at ultrasonography. Criteria for exclusion: temperature &gt; 37.5 °C, jaundice, sign of peritoneal irritation, microscopic haematuria, previous use of analgesics or antibiotic within 8 hours of enrolment, increase of serum amylases, history of peptic ulcer disease.</P>
<P>81 people were considered for the enrolment. 28 people were excluded as they did not meet the inclusion criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:18:36 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1: diclofenac, single 75 mg, 3 mL intramuscular injection (27 participants).</P>
<P>Group 2: saline, 3 mL intramuscular injection (26 participants).</P>
<P>All enrolled participants were admitted to the wards for a minimum of 3 days. Sequential assessment of pain response to treatment was performed every 15 minutes for the first 120 minutes, and then every 60 minutes for 8 hours. All participants were given analgesic rescue therapy with propoxyphene hydrochloride 2 hours after the initiation of the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:18:36 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lack of complete pain relief was observed in 6 out of 27 participants in the diclofenac group versus 19 out of 26 in the placebo group. Gallstone-related complications, assessed according to predefined criteria, were significantly lower in participants in diclofenac group (13/27) than in the placebo group (21/26). Authors stated that they did not find any adverse reaction to diclofenac or placebo, even if systematically searched.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:18:36 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 13:18:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Al-Waili-1998">
<CHAR_METHODS MODIFIED="2016-09-07 13:18:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:18:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>32 participants (26 women and 6 men, mean age 47 years) presenting with acute biliary colic diagnosed on the basis of physical examination, laboratory test, liver and renal function test, serum electrolytes, serum amylases, and ultrasonography were enrolled.</P>
<P>Included participants were seen at the emergency department within 2 hours of onset from their symptoms. Occurrence and severity of pain were rated on a 5-point scale: 0 = no pain; 1= mild pain; 2 = moderate pain; 3 = severe pain; 4 = very severe pain. Methods of random allocation were not detailed.</P>
<P>People who had received spasmolytic, pethidine, or any prostaglandin synthesis inhibitor within 2 hours were excluded from the trial, as well as those who had jaundice, liver or renal impairment, cardiovascular disease, acute cholecystitis, or history of allergy to other NSAIDs.</P>
<P>Pain severity and relief were recorded on a scale at 15-minute intervals for up to 1 hour, and then hourly for 12 hours.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:18:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1: tenoxicam, 20 mg i.v. (16 participants).</P>
<P>Group 2: hyoscine N-butylbromide, 20 mg i.v. (16 participants).</P>
<P>For both groups, an analgesic rescue therapy was planned after 1 hour with pethidine (100 mg i.v.).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:18:55 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lack of complete pain relief within 30 minutes from injection was observed in 6 out of 16 participants in the tenoxicam group versus 9 out of 16 participants in the hyoscine group.</P>
<P>In the tenoxicam group, pre-treatment mean pain score was 2.75 ± 0.93 and decreased to 0.49 ± 0.51 within 30 minutes. In the hyoscine group, the mean pain score was 2.62 ± 1.01 and decreased to 0.57 ± 0.53 within 30 minutes.</P>
<P>No participant on tenoxicam showed complications, whereas 5 participants in the hyoscine group developed acute cholecystitis according to clinical criteria.</P>
<P>Drug-related adverse events were not observed in the trial.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:18:55 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 13:19:16 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Broggini-1984">
<CHAR_METHODS MODIFIED="2016-09-07 13:19:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:19:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>30 consecutive outpatients (14 men and 16 women, mean age 46 years) with gallstones demonstrated at ultrasonography, radiography, or at operation and presenting with biliary colic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:19:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1: diclofenac sodium, 75 mg intramuscularly (14 participants)</P>
<P>Group 2: saline (16 participants)</P>
<P>Participants were randomised (methods of random allocation not detailed) to receive 75 mg of diclofenac i.m. (14 participants) or placebo (16 participants) and followed up for 24 hours. The 2 patient groups were similar regarding age, sex, weight, duration of pain, and initial intensity of pain. Before the injection and 25 minutes afterwards, the intensity of pain was recorded on a scale where 0 represents no pain and 100 unbearable pain.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:19:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>After 25 minutes, lack of complete pain relief was observed in 5 out of 14 participants in the diclofenac group versus 16 out of 16 participants in the placebo group. Mean pain intensity changed from 80.2 ± 13.07 to 9.7 ± 8.78 in the diclofenac group and from 85.7 ± 9.53 to 86.0 ± 9.87 in the placebo group.</P>
<P>Cholelithiasis-related complications were not observed and reported.</P>
<P>No side effects were observed and reported in the 2 groups.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:19:16 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-09 11:54:40 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Camp-1992">
<CHAR_METHODS MODIFIED="2016-09-07 13:19:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:19:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial included 84 people with biliary colic, presenting at emergency department.</P>
<P>Exclusion criteria were acute cholecystitis, pancreatitis, renal colic, hepatic or renal disease, peptic ulcer, ischaemic heart disease, and glaucoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:19:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Participants were allocated to 3 groups:</P>
<P>Group 1: flurbiprofen 150 mg i.m. (30 participants)</P>
<P>Group 2: hyoscine 20 mg i.m. (25 participants)</P>
<P>Group 3: pentazocine 30 mg i.m. (29 participants)</P>
<P>An analgesic rescue therapy was planned. Participants were followed up for 6 hours after treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:19:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lack of pain relief was observed in 2 out of 30 participants with flurbiprofen, 7 out of 25 participants with hyoscine, and 6 out 29 participants with pentazocine. Side effects in the flurbiprofen group were: fever (1 participant) and anxiety (1 participant); in the hyoscine group headache (1), nausea (1), dry mouth (1), and tachycardia (1 case); and in the pentazocine group: nausea (6) vomiting (4), dry mouth (1), dizziness (5).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:19:28 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-09 11:55:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Dula-2001">
<CHAR_METHODS MODIFIED="2016-09-07 13:19:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:19:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial enrolled participants presenting at the emergency department with symptoms consistent with biliary colic and diagnosis confirmed by abdominal ultrasound.</P>
<P>Exclusion criteria: age less than 18 years or greater than 65 years, person's rectal temperature &gt; 38 °C, previous allergy to ketorolac or other NSAIDs or previous adverse reactions to pethidine, pregnancy, history of renal disease, or ongoing oral anticoagulation. Enrolment was not consecutive.</P>
<P>30 participants were enrolled in the trial: 16 in the ketorolac group (mean age 42.5 ± 14.3 years; 19% males) and 14 in the pethidine group (mean age 40.6 ± 14.3 years; 21% males).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:19:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1: ketorolac 60 mg i.m. (16 participants)</P>
<P>Group 2: pethidine 1.5 mg/kg i.m. (14 participants) with a maximum of 100 mg.</P>
<P>In all groups a rescue therapy was predefined, with pethidine 1 mg/kg i.m. after 30 minutes.</P>
<P>10-point VAS (1 to 10) was used to score pain, before and 30 minutes after treatment.</P>
<P>Before discharge, participants were asked to complete a questionnaire to rate the effectiveness of treatment (0 = no effective; 1= mildly effective; 2 = moderately effective; 3 = completely effective).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:19:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The average pain score was 7.6 ± 1.9 for the ketorolac group and 7.3 ± 2.4 for the pethidine group. 30 minutes after treatment pain score decreased to 3.8 ± 2.6 for the ketorolac group and 3.9 ± 2.5 for the pethidine group.</P>
<P>Regarding complications, the need for emergency cholecystectomy was also assessed. In the 2-week follow-up period this was performed in 2 participants in the pethidine group and 2 participants in the ketorolac group.</P>
<P>Information on adverse events was not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:19:44 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 13:20:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Goldman-2001">
<CHAR_METHODS MODIFIED="2016-09-07 13:19:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:19:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial included 60 participants admitted to the emergency ward with biliary colic with gallstones demonstrated by ultrasonography performed in the previous 6 months or at the emergency ward.</P>
<P>Participants in this trial were divided into 3 groups. A fourth group of participants with low back pain was included for comparative purposes.</P>
<P>Group 1: average age 61 years; 12 females and 8 males</P>
<P>Group 2: average age 58 years; 14 females and 6 males</P>
<P>Group 3: average age 65 years; 10 females and 10 males</P>
<P>Group 4: average age 52 years; 8 females and 12 males</P>
<P>Exclusion criteria: temperature &gt; 37.5 °C, signs of peritoneal inflammation, white blood count &gt; 10.000/mm<SUP>3</SUP> or serum amylases over the normal limit, history of peptic disease, or hypersensitivity to diclofenac.</P>
<P>Severity of pain was rated on a scale of A to D (A = mild pain; D = intractable pain).</P>
<P>Response to drug administration was defined as: no response, improvement, or relief of pain. Inquiry as to severity of pain was done every 10 to 15 min by the attending internist.</P>
<P>Time lapse for the onset of the drug's alleviating effect and levels of response were recorded for each group.</P>
<P>All participants remained in emergency ward for a period of 24 hours.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:19:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1: placebo (3 mL of normal saline, i.m ) (20 participants)</P>
<P>Group 2: papaverine 80 mg i.m. injection (20 participants)</P>
<P>Group 3: diclofenac 75 mg i.m. injection (20 participants)</P>
<P>Group 4: diclofenac 75 mg i.m. injection (20 participants with low back pain)</P>
<P>Only group 1 and group 3 were considered in this review.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:20:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>15 participants in the placebo group and 13 participants receiving papaverine had no improvement versus only 1 of those receiving diclofenac. On the other hand, of the participants receiving diclofenac, 17 responded with complete pain relief, 2 with partial improvement, and only 1 participant failed to respond. 5 participants treated with placebo and 4 with papaverine needed hospitalisation; all 9 of these participants progressed to acute cholecystitis. None of the participants administered diclofenac required hospitalisation or surgery within the period of observation.</P>
<P>Group 4, which included participants with low back pain who received diclofenac, showed pain relief in 5 participants (25%), improvement in 7 participants (35%), and no response in the remaining 8 participants (40%). The trial did not report data on adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:19:56 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 13:20:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Grossi-1986">
<CHAR_METHODS MODIFIED="2016-09-07 13:20:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:20:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial included 54 participants presenting at the emergency department for biliary colic; diagnosis was confirmed by ultrasonography.</P>
<P>Exclusion criteria: hypersensitivity to NSAIDs, peptic ulcer, and bronchial asthma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:20:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Participants were randomly allocated to:</P>
<P>Group 1: diclofenac 75 mg i.m. (16 participants)</P>
<P>Group 2: butyl-scopolamine bromide 20 mg i.m. (15 participants)</P>
<P>15 participants who were allocated to 1 mg glucagon treatment were not included in the analysis.</P>
<P>In all of the groups, a rescue therapy was planned after 60 minutes with the same drugs.</P>
<P>The intensity of pain was estimated before and 30 minutes after injection with an analogue chromatic continue scale (0 to 100 mm).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:20:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lack of pain relief was observed in 5 out of 16 participants on diclofenac and in 10 out of 15 on scopolamine.</P>
<P>No side effects were experienced in participants on diclofenac or scopolamine; conversely, in 3 participants on glucagon a sharp increase in glycaemia was observed without concomitant changes in serum amylase. All 3 treatments caused a significant decrease in systolic blood pressure.</P>
<P>No gallstone-related complications were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:20:19 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 13:20:41 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Henderson-2002">
<CHAR_METHODS MODIFIED="2016-09-07 13:20:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:20:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>534 consecutive participants attending the emergency department with a history and physical examination consistent with biliary colic were enrolled.</P>
<P>Inclusion criteria: age between 18 and 65 years, pain of moderate to severe intensity on a 4-point (none, mild, moderate, severe) verbal rating system, abdominal pain felt by the clinician to originate from the gallbladder (e.g. right upper quadrant or epigastric pain), and a history of known cholelithiasis or a bedside, emergency physician-performed ultrasonography consistent with cholelithiasis.</P>
<P>Exclusion criteria: age under 18 years or over 65 years, history of known cholecystectomy, pregnancy, history of renal insufficiency, history of active peptic ulcer disease in the previous 6 months, history of bleeding, anticoagulation regimen in the previous 4 weeks, immunocompromised because of different underlying medical conditions (including diabetes mellitus, HIV, end-stage hepatic disease, and cancer), and a patient history of allergy to any opioid or non-opioid analgesic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:20:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Of 534 enrolled participants, 324 completed the protocol and had completed study forms.</P>
<P>Group 1: ketorolac 30 mg i.v. (175 participants)</P>
<P>Group 2: pethidine 50 mg i.v. (149 participants)</P>
<P>Immediately before drug administration, participants were asked by the physician to rate the severity of their pain using a 4-point visual rating system (VRS) (none, mild, moderate, or severe) and a VAS. The VAS was a 100-millimetre horizontal, not-numbered scale bounded by the descriptors "no pain" and "maximum pain". At time 0 (baseline), the study medication was administered and vital signs were recorded. At 30 minutes, 1 h, and 2 h, vital signs were repeated, and the participants pain was reassessed using both the VRS and VAS.</P>
<P>Participants with inadequate subjective pain relief at 1 h were given a supplementary dose of pethidine 50 mg i.v. as a rescue drug. Also, at 2 h participants were asked to rate overall pain relief on a 5-point categorical scale (none, a little, some, a lot, complete), and both participants and physicians were asked to rate drug tolerability (poor, fair, good, very good, or excellent).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:20:41 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>No significant difference in pain relief was found between the 2 groups in the VRS at 30 minutes, 1 h, or 2 h. No significant differences were found between the 2 groups in the change in the mean VAS at 30 minutes or at 1 h. At 2 hours, ketorolac was equal in efficacy to pethidine for analgesia with a total change in the VAS score of 6.7 cm vs 6.2 cm (P = 0.29). Lack of pain relief (i.e. the need for a further dose of pethidine) at 1 hour of observation was observed in 129 out of 175 participants treated with ketorolac versus 125 out of 149 treated with pethidine (P = NS). Drowsiness was the most frequent side effect, observed in 34.6% of participants treated with ketorolac and 42.1% of those treated with pethidine (P = NS). Nausea and dizziness were significantly more frequent in the pethidine group than in the ketorolac group (16.4% vs 6.8% and 17.9% vs 6.8%).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:20:30 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-09 12:23:41 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Kumar-2004">
<CHAR_METHODS MODIFIED="2016-09-07 13:20:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:20:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial included 72 consecutive participants with biliary colic, presenting with severe pain, lasting less than 6 h, attending the emergency department. The presence of gallstones was confirmed by ultrasonography.</P>
<P>Exclusion criteria were: severe pain lasting more than 6 h, fever, leucocytosis, abnormal liver function tests, signs of peritonitis or ultrasound evidence of acute cholecystitis, or common bile duct stones. The trial also excluded people who had received analgesics or antibiotics before hospital presentation, and those with pregnancy or significant systemic disease such as diabetes mellitus, uraemia, cardiovascular or respiratory disease. Similarly, people with contraindications to receive diclofenac (acute peptic ulcer, gastrointestinal bleeding, asthma or NSAID-induced allergy) or hyoscine (glaucoma, prostatic hypertrophy with urinary retention, gastrointestinal mechanical stenosis, porphyria), and those receiving medications likely to have adverse interactions with diclofenac or hyoscine (lithium, digoxin, L-Dopa, antidepressants, phenothiazines) were also excluded from the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:20:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1: diclofenac single dose of 75 mg i.m. (36 participants)</P>
<P>Group 2: hyoscine-N-butylbromide single dose of 20 mg i.m. (36 participants)</P>
<P>In both groups, pain severity was recorded on a 10-point VAS 30 min, 1 h, 2 h, and 4 h after treatment. Participants were then closely followed up to 72 h for the persistence or relapse of pain, or the development of acute cholecystitis (which was confirmed by ultrasonography). No rescue therapy was planned.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-09 12:23:41 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>No participant in either group had complete pain relief within 1 hour from having received injection. However, the number of participants without complete pain relief at 2 h was significantly less frequent in the group receiving diclofenac as compared to the group receiving scopolamine (16 out of 36 versus 29 out of 36). Pain intensity by VAS decreased from 9.58 ± 0.54 to 5.15 ± 1.2 in the diclofenac group and from 9.61 ± 0.48 to 5.76 ± 0.97 in the hyoscine group.</P>
<P>Progression to cholecystitis was observed in 6 out of 36 participants in the diclofenac group and in 19 out of 36 participants in the hyoscine group (P = 0.003).</P>
<P>The trial did not report data on adverse events.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:20:52 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 13:21:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Lundstam--1985">
<CHAR_METHODS MODIFIED="2016-09-07 13:21:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:21:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>47 participants presenting at the emergency room for biliary colic pain. Only people with a confirmed diagnosis of cholelithiasis (oral cholecystogram or ultrasound or operation) were included in the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:21:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1 (25 participants): diclofenac sodium (50 mg i.m.)</P>
<P>Group 2 (22 participants): placebo (saline) (50 mg i.m.)</P>
<P>Before injection the surgeon rated the pain intensity as either moderate or severe. The analgesic effect was evaluated at 15 and 30 minutes as nil, partial, or complete relief. The participant also rated the pain on a 100-millimetre VAS before and 30 minutes after the injection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:21:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Overall, at 30 minutes after injection lack of complete pain relief was observed in 14 out of 25 participants in the diclofenac group versus 16 out of 20 participants in the placebo group. Pain estimated on the visual scale was reduced by 58% (from 63 ± 5 to 27 ± 5 mm) in the diclofenac group and by 39% (from 66 ± 4 to 41 ± 6 mm) in the placebo group. As from clinical evaluation, cholecystitis developed in 8 out of 25 participants on diclofenac versus 7 out of 22 participants on saline.</P>
<P>No participant had evidence of common bile duct disease or pancreatitis.</P>
<P>No serious side effects were recorded in the 2 groups, even if a slight but significant decrease in systolic blood pressure was reported in both groups after the treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 13:21:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Magrini-1985">
<CHAR_METHODS MODIFIED="2016-04-21 11:03:34 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:21:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>60 participants presenting at 2 Italian emergency wards with biliary colic were enrolled.</P>
<P>Exclusion criteria were: a history of haemorrhagic disorder; peptic ulcer; severe hepatic, renal respiratory, or cardiac insufficiency; and diabetes mellitus. Severely disabled people, people unable to co-operate, narcotic addicts, people with known hypersensitivity to ketoprofen or acetylsalicylic-acid were also excluded.</P>
<P>Pain intensity was assessed before and 15, 30, 60, 120, and 180 minutes after treatment by asking the participants to rate pain according to a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe).</P>
<P>Rescue analgesic therapy was planned after 3 hours from the beginning of the trial with the same drug.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:21:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Group 1: ketoprofen 200 mg i.v. (20 participants)</P>
<P>Group 2: lysine acetylsalicylate, 1.8 g i.v. (20 participants)</P>
<P>Group 3: placebo 10 mL i.v. (20 participants)</P>
<P>Only group 1 and group 3 were considered in this review.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:21:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>30 minutes after injection, lack of complete pain relief was observed in 3 out of 20 participants in ketoprofen group, 4 out of 20 participants in the lysine acetylsalicylic-acid group, and 16 out of 20 participants in the placebo group.</P>
<P>All treatments were well tolerated.</P>
<P>Only 1 participant experienced vomiting (in the acetylsalicylic-acid group) and 1 drowsiness (in the ketoprofen group). No complication was reported.</P>
<P>Adverse events were: restlessness (2 with placebo and 1 with acetylsalicylic-acid), vomiting (1 participant with acetylsalicylic-acid), and drowsiness (1 case with ketoprofen). Blood pressure was slightly but significantly decreased in the 2 treatment groups but not in the placebo subset.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 13:21:19 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-09 11:57:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Olsen--2008">
<CHAR_METHODS MODIFIED="2016-09-07 13:21:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 13:21:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>51 participants presenting with suspected biliary colic, 5 of them refused and thus 46 were enrolled and randomised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:21:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>- ketorolac 30 mg i.v. (21 participants)</P>
<P>- butorphanol 1 mg i.v. (25 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-07 13:21:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Pain level was assessed using 1-to-10 "faces" visual analogue pain scale basal and at 15 and 30 minutes after medication infusion.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ED: emergency department; i.m.: intramuscularly; i.v.: intravenously; NS: non-significant; NSAIDs: non-steroid anti-inflammatory drugs; VAS: visual analogue scale.</P>
<P>Hyoscine butylbromide, butyl-scopolamine bromide, and scopolamine is the one and the same drug.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-09-07 13:22:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-09-07 13:21:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Chang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 13:21:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not relevant as it refers to dental pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-09-07 13:21:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Chaudhary-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 13:21:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The study compares 2 NSAIDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-09-07 03:21:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kantor-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 03:21:57 +0200" MODIFIED_BY="[Empty name]">
<P>It is a review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-09-07 03:22:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marsala-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 03:22:08 +0200" MODIFIED_BY="[Empty name]">
<P>The study compares a different type of administration of naproxen sodium (i.v. versus i.m.).
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-09-07 13:21:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Niinikoski-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 13:21:55 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The study compares 2 NSAIDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-09-07 13:22:00 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Thornell-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 13:22:00 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>It is not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>i.m.: intramuscularly; i.v.: intravenously; NSAIDs: non-steroid anti-inflammatory drugs</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-01-08 13:45:54 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-09-09 12:27:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-09-09 12:27:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-NCT02268955">
<CHAR_STUDY_NAME MODIFIED="2016-08-16 15:07:03 +0200" MODIFIED_BY="[Empty name]">
<P>Assessment of the analgesic efficacy of intravenous ibuprofen in biliary colic</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-08-19 11:24:07 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-08-16 17:09:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Patients referring at the emergency department for biliary colic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 13:22:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Drug: ibuprofen i.v.; placebo: saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-09 12:27:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Primary: pain level: VAS at 15 minutes post-administration</P>
<P>Secondary: changes in pain level (VAS) at 30, 45, 60, and 90 minutes post-administration</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-09-07 13:22:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>16 September 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-09-09 12:27:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Dr Dan Quan by phone </P>
<P>Dr Mary Mulrow by phone</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-09-07 13:22:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Eligibility 18.55 years</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>i.v.: intravenously; VAS: visual analogue scale.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-09-09 12:26:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-09-09 12:25:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:17:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akriviadis-1997">
<DESCRIPTION>
<P>"Random allocation was performed using a random number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Al-Waili-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Broggini-1984">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Camp-1992">
<DESCRIPTION>
<P>Random allocation was performed using computer-generated sequences.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:25:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dula-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:20:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Goldman-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 15:59:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Grossi-1986">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:36:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henderson-2002">
<DESCRIPTION>
<P>Computed-generated list of random number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-09 12:24:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Kumar-2004">
<DESCRIPTION>
<P>Randomized block design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:21:13 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Lundstam--1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:21:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Magrini-1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-09 12:25:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Olsen--2008">
<DESCRIPTION>
<P>The pharmacy supplied the participants with their medication via a computed-generated randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-09-09 12:21:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-10 08:04:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akriviadis-1997">
<DESCRIPTION>
<P>"The sealed-opaque envelope method was used to conceal allocation concealment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Al-Waili-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Broggini-1984">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Camp-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-09 12:21:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Dula-2001">
<DESCRIPTION>
<P>Enrollment was not consecutive<BR/>
<BR/>When a trial patient was identified, the emergency department nurse was instructed to refer to a posted randomised schedule in order to assign a patient into a treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:20:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Goldman-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 15:59:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Grossi-1986">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:36:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henderson-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:46:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:21:13 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Lundstam--1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:21:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Magrini-1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:54:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olsen--2008">
<DESCRIPTION>
<P>Medicaments were given by a nurse uninvolved in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-03-04 11:51:06 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-09-08 13:54:32 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 18:09:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akriviadis-1997">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-20 17:57:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Al-Waili-1998">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-20 17:57:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Broggini-1984">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-20 17:54:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Camp-1992">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-08 13:26:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dula-2001">
<DESCRIPTION>
<P>Unclear. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-20 17:54:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Goldman-2001">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-07 13:20:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Grossi-1986">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-08 13:36:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henderson-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-08 13:46:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-20 17:55:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Lundstam--1985">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-20 17:55:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Magrini-1985">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-08 13:54:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olsen--2008">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-09-09 12:24:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:18:47 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Akriviadis-1997">
<DESCRIPTION>
<P>The trial protocol is available, and all of the trial's prespecified outcomes that are of interest in the review have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Al-Waili-1998">
<DESCRIPTION>
<P>The trial protocol is available, and all of the trial's prespecified outcomes that are of interest in the review have been reported or similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 18:09:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Broggini-1984">
<DESCRIPTION>
<P>There is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Camp-1992">
<DESCRIPTION>
<P>The trial protocol is available and all of the trial's prespecified outcomes that are of interest in the review have been reported or similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dula-2001">
<DESCRIPTION>
<P>The trial protocol is available and all of the trial's prespecified outcomes that are of interest in the review have been reported or similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:20:14 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Goldman-2001">
<DESCRIPTION>
<P>The trial protocol is available, and all of the trial's prespecified outcomes that are of interest in the review have been reported or similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 18:09:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grossi-1986">
<DESCRIPTION>
<P>There is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-09 12:22:35 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Henderson-2002">
<DESCRIPTION>
<P>The trial protocol is available, and all of the trial's prespecified outcomes that are of interest in the review have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-09 12:24:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Kumar-2004">
<DESCRIPTION>
<P>The trial protocol is available, and all of the trial's prespecified outcomes of interest to the review have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 18:09:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lundstam--1985">
<DESCRIPTION>
<P>There is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:55:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Magrini-1985">
<DESCRIPTION>
<P>There is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:55:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsen--2008">
<DESCRIPTION>
<P>There is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2016-09-09 12:26:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-07 13:18:47 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Akriviadis-1997">
<DESCRIPTION>
<P>3 mL of diclofenac (containing 75 mg of active principle) or 3 mL of saline were prepared by the pharmacist and taken to the ward to be injected. Charting of the type of injection given was done by the pharmacist.</P>
<P>As diclofenac was slightly yellow in colour, masking of the participant was achieved by carrying the syringe with medication in a wrapped bag that was opened immediately before the injection in order that the participant could not see the syringe.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-07 13:19:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Al-Waili-1998">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-07 13:19:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Broggini-1984">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-09 12:19:16 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Camp-1992">
<DESCRIPTION>
<P>The person who administered the treatment was different from the one who took care of the patient.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-08 13:28:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dula-2001">
<DESCRIPTION>
<P>The physician and the patient were blinded because both medications were given i.m. and only the nurse knew the identity of the medication administered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-08-16 15:32:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldman-2001">
<DESCRIPTION>
<P>Neither the participants nor the attending intern were aware of the type of drug administered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-07 13:20:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Grossi-1986">
<DESCRIPTION>
<P>Injection was made by a member of the medical staff not involved in the subsequent follow-up. The participant was unaware of the identity of the treatment administered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-09 12:22:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Henderson-2002">
<DESCRIPTION>
<P>Study drugs were administered by the participant primary nurse and were identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-08 13:47:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2004">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-07 13:21:13 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Lundstam--1985">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-07 13:21:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Magrini-1985">
<DESCRIPTION>
<P>The 3 drugs were given from identical vials of identical appearance, containing a freeze-dried powder to be dissolved in 10 mL sterile water and injected in a 2-minutes intravenous dose.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-09-09 12:26:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Olsen--2008">
<DESCRIPTION>
<P>The treating physician and the participants were blind to the study medication used. At the end of the study, when all the participants were enrolled and data collected, the pharmacy provided information as to which study drug was actually administered to each participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2016-09-09 11:51:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-06 23:27:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akriviadis-1997">
<DESCRIPTION>
<P>"The outcome assessment was performed by the same physician/personnel who administered treatment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-07 13:19:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Al-Waili-1998">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-07 13:19:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Broggini-1984">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-03-04 13:27:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Camp-1992">
<DESCRIPTION>
<P>The outcome assessment was performed by the same physician/personnel who administered treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-08 13:30:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dula-2001">
<DESCRIPTION>
<P>The outcome assessment was performed by the same physician/personnel who administered treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-03-04 13:29:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldman-2001">
<DESCRIPTION>
<P>The outcome assessment was performed by the same physician/personnel who administered treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-07 13:20:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Grossi-1986">
<DESCRIPTION>
<P>Injection was made by a member of the medical staff not involved in the subsequent follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-08 13:38:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henderson-2002">
<DESCRIPTION>
<P>The outcome assessment was performed by the same physician/personnel who administered treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-08 13:47:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2004">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-07 13:21:13 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Lundstam--1985">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-04-20 17:54:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Magrini-1985">
<DESCRIPTION>
<P>The outcome assessment was performed by the same physician/personnel who administered treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-09-09 11:51:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Olsen--2008">
<DESCRIPTION>
<P>Drug administration was made by a nurse not involved in the subsequent follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-09-08 13:58:32 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-20 17:56:48 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Akriviadis-1997">
<DESCRIPTION>
<P>There was no statement on conflict of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Al-Waili-1998">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Broggini-1984">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:19:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Camp-1992">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:29:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dula-2001">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:20:14 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Goldman-2001">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:20:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Grossi-1986">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:38:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henderson-2002">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:47:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2004">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:21:13 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Lundstam--1985">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 13:21:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Magrini-1985">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-08 13:58:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olsen--2008">
<DESCRIPTION>
<P>No risk of for-profit bias on the side of researchers, manufacturers, or funding bodies or any personal conflicts by the authors of the trial publication were observed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-09-09 12:00:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-09-09 12:00:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-09-07 13:23:20 +0200" MODIFIED_BY="Dimitrinka Nikolova">Non-steroid anti-inflammatory drugs versus placebo for biliary colic</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Non-steroid anti-inflammatory drugs versus placebo for biliary colic</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with biliary colic<BR/>
<B>Settings:</B> emergency departments<BR/>
<B>Intervention:</B> NSAIDs versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>NSAIDs versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Lack of pain relief</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.27 </B>
<BR/>(0.19 to 0.4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>208<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>784 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>212 per 1000</B>
<BR/>(149 to 314)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>800 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>216 per 1000</B>
<BR/>(152 to 320)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Cholelithiasis-related complications</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.66 </B>
<BR/>(0.38 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>140<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>471 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>311 per 1000</B>
<BR/>(179 to 541)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>318 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>210 per 1000</B>
<BR/>(121 to 366)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>NSAIDs:</B> non-steroid anti-inflammatory drugs; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded one level (-1) for risk of bias because the overall risk of bias in four out of five studies was unclear.<BR/>
<SUP>2</SUP>Downgraded one level (-1) for risk of bias because the overall risk of bias in two out of three studies was unclear.<BR/>
<SUP>3</SUP>Downgraded two levels (-2) for imprecision: wide 95% CI overlapping 1 and including appreciable benefits (RR &lt; 0.75); the required information size was not reached.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-09-09 11:59:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" READONLY="YES">
<TITLE MODIFIED="2016-09-07 13:24:06 +0200" MODIFIED_BY="Dimitrinka Nikolova">Non-steroid anti-inflammatory drugs versus opioids for biliary colic</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Non-steroid anti-inflammatory drugs versus opioids for biliary colic</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with biliary colic<BR/>
<B>Settings:</B> emergency departments<BR/>
<B>Intervention:</B> NSAIDs versus opioids<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>NSAIDs versus opioids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Lack of pain relief</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.47 to 2.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>459<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>180 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>176 per 1000</B>
<BR/>(84 to 372)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>203 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>199 per 1000</B>
<BR/>(95 to 420)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Cholelithiasis-related complications</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.14 to 5.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>143 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>126 per 1000</B>
<BR/>(20 to 774)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>143 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>126 per 1000</B>
<BR/>(20 to 775)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>NSAIDs:</B> non-steroid anti-inflammatory drugs; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded one level (-1) for risk of bias because the overall risk of bias was unclear in three and high in one out of four studies.<BR/>
<SUP>2</SUP>Downgraded two levels (-2) for imprecision: wide 95% CI including appreciable benefits and harms (RR &lt; 0.75 and RR &gt; 1.25); the required information size was not reached.<BR/>
<SUP>3</SUP>Downgraded one level (-1) for risk of bias because of only one study which is also at overall high risk of bias.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-09-09 12:00:48 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="3" READONLY="YES">
<TITLE MODIFIED="2016-09-07 13:24:39 +0200" MODIFIED_BY="Dimitrinka Nikolova">Non-steroid anti-inflammatory drugs versus spasmolytic drugs for biliary colic</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Non-steroid anti-inflammatory drugs versus spasmolytic drugs for biliary colic</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with biliary colic<BR/>
<B>Settings:</B> emergency departments<BR/>
<B>Intervention:</B> NSAIDs versus spasmolytic drugs<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>NSAIDs versus spasmolytic drugs</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Lack of pain relief</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.51 </B>
<BR/>(0.37 to 0.71)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>190<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>598 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>305 per 1000</B>
<BR/>(221 to 424)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>615 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>314 per 1000</B>
<BR/>(228 to 437)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Cholelithiasis-related complications</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.27 </B>
<BR/>(0.12 to 0.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>104<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>462 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>125 per 1000</B>
<BR/>(55 to 263)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>420 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>113 per 1000</B>
<BR/>(50 to 239)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>NSAIDs:</B> non-steroid anti-inflammatory drugs; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded one level (-1) for risk of bias because the overall risk of bias was unclear in all the studies.<BR/>
<SUP>2</SUP>Downgraded one level (-1) for imprecision: the required information size was not reached.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-01-29 08:15:50 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-09-09 11:36:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2016-09-09 11:31:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>NSAIDs versus placebo</NAME>
<DICH_OUTCOME CHI2="2.6975863159111615" CI_END="0.4011245580533539" CI_START="0.18744657899393036" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2742069039202941" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="80" I2="0.0" I2_Q="100.0" ID="CMP-001.01" LOG_CI_END="-0.3967207483884194" LOG_CI_START="-0.7271224812899961" LOG_EFFECT_SIZE="-0.5619216148392078" METHOD="MH" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.6096372389755005" P_Q="0.0" P_Z="2.6160279943673236E-11" Q="1.3089426355628202E-30" RANDOM="NO" SCALE="40.11" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="102" WEIGHT="99.99999999999999" Z="6.66670914554504">
<NAME>Lack of pain relief</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5781927523619794" CI_START="0.11106553959389183" EFFECT_SIZE="0.253411306042885" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.2379273565064656" LOG_CI_START="-0.9544206691034934" LOG_EFFECT_SIZE="-0.5961740128049795" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="1" O_E="0.0" SE="0.420871718518592" STUDY_ID="STD-Akriviadis-1997" TOTAL_1="27" TOTAL_2="26" VAR="0.17713300344879293" WEIGHT="23.91757450566315"/>
<DICH_DATA CI_END="0.738431232591737" CI_START="0.1932692484875172" EFFECT_SIZE="0.37777777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.13168994273053372" LOG_CI_START="-0.7138372420636058" LOG_EFFECT_SIZE="-0.4227635923970698" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="2" O_E="0.0" SE="0.3419562053038533" STUDY_ID="STD-Broggini-1984" TOTAL_1="14" TOTAL_2="16" VAR="0.11693404634581107" WEIGHT="19.11176800548467"/>
<DICH_DATA CI_END="0.4503534857660061" CI_START="0.055358176877509824" EFFECT_SIZE="0.15789473684210525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="19" LOG_CI_END="-0.3464464714389693" LOG_CI_START="-1.256818221027364" LOG_EFFECT_SIZE="-0.8016323462331666" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="3" O_E="0.0" SE="0.5347568721210619" STUDY_ID="STD-Goldman-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.28596491228070176" WEIGHT="23.47465645926198"/>
<DICH_DATA CI_END="0.9820408231852995" CI_START="0.16292601714970653" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="-0.007870458327507272" LOG_CI_START="-0.7880095590165679" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="4" O_E="0.0" SE="0.4582575694955841" STUDY_ID="STD-Lundstam--1985" TOTAL_1="25" TOTAL_2="20" VAR="0.21000000000000008" WEIGHT="13.72786927442221"/>
<DICH_DATA CI_END="0.6170559326378815" CI_START="0.10128741446956972" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.20967546783867852" LOG_CI_START="-0.9944445148172463" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="5" O_E="0.0" SE="0.4609772228646444" STUDY_ID="STD-Magrini-1985" TOTAL_1="20" TOTAL_2="20" VAR="0.21250000000000002" WEIGHT="19.768131755167982"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.697024033790985" CI_END="1.150108324868932" CI_START="0.379110759503833" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6603169243270551" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="32" I2="25.844190673052164" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.06073874702948972" LOG_CI_START="-0.4212338897312203" LOG_EFFECT_SIZE="-0.18024757135086533" METHOD="MH" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.25962648917600994" P_Q="1.0" P_Z="0.1426564204110873" Q="0.0" RANDOM="YES" SCALE="219.58" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07406789418879381" TOTALS="YES" TOTAL_1="72" TOTAL_2="68" WEIGHT="99.99999999999999" Z="1.4659701452051754">
<NAME>Cholelithiasis-related complications</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9201080849872542" CI_START="0.3862143764297926" EFFECT_SIZE="0.5961199294532628" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" LOG_CI_END="-0.0361611531366479" LOG_CI_START="-0.4131715640938558" LOG_EFFECT_SIZE="-0.22466635861525186" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="22" O_E="0.0" SE="0.2214577816278964" STUDY_ID="STD-Akriviadis-1997" TOTAL_1="27" TOTAL_2="26" VAR="0.049043549043549045" WEIGHT="65.10607985914717"/>
<DICH_DATA CI_END="1.9371598241474748" CI_START="0.006373082312802401" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2871654533891674" LOG_CI_START="-2.195650472267817" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="25" O_E="0.0" SE="1.4584183648679576" STUDY_ID="STD-Goldman-2001" TOTAL_1="20" TOTAL_2="20" VAR="2.1269841269841274" WEIGHT="3.6415783805002904"/>
<DICH_DATA CI_END="2.3227957723302985" CI_START="0.4354499162339476" EFFECT_SIZE="1.0057142857142858" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.36601102691213316" LOG_CI_START="-0.36106178865642236" LOG_EFFECT_SIZE="0.002474619127855411" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="28" O_E="0.0" SE="0.4270861709334516" STUDY_ID="STD-Lundstam--1985" TOTAL_1="25" TOTAL_2="22" VAR="0.1824025974025974" WEIGHT="31.252341760352525"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-09-09 11:31:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>NSAIDs versus opioids</NAME>
<DICH_OUTCOME CHI2="6.234215702128023" CI_END="2.0673855487531942" CI_START="0.4681307170836413" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9837716602068745" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="39" I2="51.878469668992" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.3154214761831003" LOG_CI_START="-0.32963286106814504" LOG_EFFECT_SIZE="-0.007105692442522404" METHOD="MH" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.10075489836183316" P_Q="1.0" P_Z="0.9655576076425555" Q="0.0" RANDOM="YES" SCALE="25.31" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.28674993068824584" TOTALS="YES" TOTAL_1="242" TOTAL_2="217" WEIGHT="100.0" Z="0.04318055229861335">
<NAME>Lack of pain relief</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours opioids</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4684579548404673" CI_START="0.07070489158479648" EFFECT_SIZE="0.32222222222222224" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.16686151623697032" LOG_CI_START="-1.1505505393177078" LOG_EFFECT_SIZE="-0.49184451154036873" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="14" O_E="0.0" SE="0.7738543627276671" STUDY_ID="STD-Camp-1992" TOTAL_1="30" TOTAL_2="29" VAR="0.5988505747126437" WEIGHT="16.21175186024763"/>
<DICH_DATA CI_END="2.037454891019978" CI_START="0.09394379764853564" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.30908800229644484" LOG_CI_START="-1.0271318875797806" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="15" O_E="0.0" SE="0.7849021777084254" STUDY_ID="STD-Dula-2001" TOTAL_1="16" TOTAL_2="14" VAR="0.6160714285714286" WEIGHT="15.902521017715127"/>
<DICH_DATA CI_END="2.54030392660578" CI_START="1.0483443040163107" EFFECT_SIZE="1.631904761904762" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="24" LOG_CI_END="0.4048856795142287" LOG_CI_START="0.0205039398776666" LOG_EFFECT_SIZE="0.21269480969594767" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="16" O_E="0.0" SE="0.22578773658281448" STUDY_ID="STD-Henderson-2002" TOTAL_1="175" TOTAL_2="149" VAR="0.050980101991190414" WEIGHT="42.51068679609106"/>
<DICH_DATA CI_END="4.022988748224578" CI_START="0.5072885991618207" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6045488179078731" LOG_CI_START="-0.29474489793638664" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="19" O_E="0.0" SE="0.5282495802626057" STUDY_ID="STD-Olsen--2008" TOTAL_1="21" TOTAL_2="25" VAR="0.2790476190476191" WEIGHT="25.37504032594618"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="13.49" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Cholelithiasis-related complications</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours opioids</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.422023478166071" CI_START="0.1412065076964518" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7341613938080769" LOG_CI_START="-0.8501452877634506" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="24" O_E="0.0" SE="0.9306295871996703" STUDY_ID="STD-Dula-2001" TOTAL_1="16" TOTAL_2="14" VAR="0.8660714285714286" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-09-09 11:31:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="3">
<NAME>NSAIDs versus spasmolytic drugs</NAME>
<DICH_OUTCOME CHI2="1.6650866316658464" CI_END="0.7082980790565956" CI_START="0.3702568223781679" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5121056493030081" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.14978393603056986" LOG_CI_START="-0.4314969303924551" LOG_EFFECT_SIZE="-0.29064043321151245" METHOD="MH" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.6447235970917149" P_Q="1.0" P_Z="5.251332625757155E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="92" WEIGHT="100.0" Z="4.044149847159156">
<NAME>Lack of pain relief</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Spasmolytic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NDSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours spasmolytic drugs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.434221302196818" CI_START="0.3098855412087955" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.15661616870106745" LOG_CI_START="-0.50879868681243" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="17" O_E="0.0" SE="0.39086797998528583" STUDY_ID="STD-Al-Waili-1998" TOTAL_1="16" TOTAL_2="16" VAR="0.1527777777777778" WEIGHT="16.08321978828215"/>
<DICH_DATA CI_END="1.045021647023783" CI_START="0.05424705082911834" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.019125286701242996" LOG_CI_START="-1.265623867497044" LOG_EFFECT_SIZE="-0.6232492903979004" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="18" O_E="0.0" SE="0.7546680127869535" STUDY_ID="STD-Camp-1992" TOTAL_1="30" TOTAL_2="25" VAR="0.5695238095238094" WEIGHT="13.6463683052091"/>
<DICH_DATA CI_END="1.0538039226960025" CI_START="0.2085080134621836" EFFECT_SIZE="0.46875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.022759810864267385" LOG_CI_START="-0.6808772493927169" LOG_EFFECT_SIZE="-0.32905871926422475" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="20" O_E="0.0" SE="0.4133198922545749" STUDY_ID="STD-Grossi-1986" TOTAL_1="16" TOTAL_2="15" VAR="0.1708333333333334" WEIGHT="18.44670369982182"/>
<DICH_DATA CI_END="0.8221910953346159" CI_START="0.3702296535477053" EFFECT_SIZE="0.5517241379310345" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="29" LOG_CI_END="-0.08502723111682373" LOG_CI_START="-0.4315287993692389" LOG_EFFECT_SIZE="-0.2582780152430313" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="21" O_E="0.0" SE="0.20353673640189404" STUDY_ID="STD-Kumar-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.0414272030651341" WEIGHT="51.82370820668693"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7410230229200788" CI_END="0.5708808333860873" CI_START="0.12329602693336512" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2653061224489796" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.2434545376456042" LOG_CI_START="-0.9090509177977496" LOG_EFFECT_SIZE="-0.5762527277216769" METHOD="MH" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.38933339437042824" P_Q="1.0" P_Z="6.894204308500355E-4" Q="0.0" RANDOM="NO" SCALE="219.58" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="3.3937522078148348">
<NAME>Cholelithiasis-related complications</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Spasmolytic drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours spasmolytic drugs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5189644156550421" CI_START="0.0054408534688110965" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.18154759988933333" LOG_CI_START="-2.2643329702057833" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="23" O_E="0.0" SE="1.4367223541779577" STUDY_ID="STD-Al-Waili-1998" TOTAL_1="16" TOTAL_2="16" VAR="2.0641711229946527" WEIGHT="22.448979591836736"/>
<DICH_DATA CI_END="0.6979711578650845" CI_START="0.14287551937644222" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.15616252327775718" LOG_CI_START="-0.8450421778606135" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2016-09-09 11:30:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" ORDER="27" O_E="0.0" SE="0.40465131911125596" STUDY_ID="STD-Kumar-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.16374269005847952" WEIGHT="77.55102040816327"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-09-09 12:26:06 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-09-09 11:38:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeAAAAFzCAYAAADmJtp4AAAtMElEQVR42u2df4RVz//HI0mSRPKx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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-09-09 12:26:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUgAAAK9CAIAAADJwWJTAAAf30lEQVR42u3dza4dR9XGcUtIiIEH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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-09-09 12:26:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="fig3.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-09-07 13:29:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>TSA - Lack of pain relief - NSAIDs versus placebo.<BR/>
<BR/>Trial Sequential Analysis was performed based on lack of complete pain relief occurrence of 78.4% in the placebo group; a relative risk reduction of 20%; a risk of type I error of 5%; and a power of 80%. There was no diversity adjustment (D<SUP>2 </SUP>= 0). The resulting information size was 266.</P>
<P>The blue line represents the cumulative Z-score of the meta-analysis. The green-dashed lines represent the conventional (&#945; = 5%) boundaries for statistical significance. The two red-dashed inward-sloping lines represent the trial sequential monitoring boundaries. The two red-dashed outward-sloping lines represent the futility boundaries.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABAgAAALTCAYAAACbsDDMAACAAElEQVR42uzdB7yW8//HcaGiiZKQ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</FILE>
</FIGURE>
<FIGURE FILENAME="Fig4.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-09-07 13:29:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>TSA - Lack of pain relief - NSAIDs versus spasmolytic drugs.</P>
<P>Trial Sequential Analysis was performed based on lack of complete pain relief occurrence of 56% in the spasmolytic drugs group; a relative risk reduction of 20%; a risk of type I error of 5%; and a power of 80%. There was no diversity adjustment (D<SUP>2 </SUP>= 0). The resulting information size was 626.</P>
<P>The blue line represents the cumulative Z-score of the meta-analysis. The green-dashed lines represent the conventional (&#945; = 5%) boundaries for statistical significance. The two red-dashed inward-sloping lines represent the trial sequential monitoring boundaries.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABAgAAALTCAYAAACbsDDMAACAAElEQVR42uzdCbxM9f/HcVuEqFC0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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Fig5.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-09-07 13:29:42 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>TSA - Cholelithiasis-related complications - NSAIDs versus placebo.</P>
<P>Trial Sequential Analysis was performed based on cholelithiasis-related complications occurrence of 47% in the placebo group; a relative risk reduction of 20%; a risk of type I error of 5%; and a power of 80%; heterogeneity adjustment based on D<SUP>2 </SUP>= 50%. The resulting information size was 1788.</P>
<P>The blue line represents the cumulative Z-score of the meta-analysis. The green-dashed lines represent the conventional (&#945; = 5%) boundaries for statistical significance. The two pieces of red inward-sloping lines represent the trial sequential monitoring boundaries.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABAgAAALTCAYAAACbsDDMAACAAElEQVR42uzdB5wURd7GcVAP9cxZ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</FILE>
</FIGURE>
<FIGURE FILENAME="Fig6.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-09-07 13:29:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>TSA - Cholelithiasis-related complications - NSAIDs versus spasmolytic drugs.<BR/>
</P>
<P>Trial Sequential Analysis was performed based on cholelithiasis-related complications occurrence of 46% in the placebo group; a relative risk reduction of 20%; a risk of type I error of 5%; and a power of 80%. As only two studies were included, we used a more conservative heterogeneity adjustment based on D<SUP>2 </SUP>= 50% rather than data-based diversity (D<SUP>2 </SUP>was 0). The resulting information size was 1800.</P>
<P>The blue line represents the cumulative Z-score of the meta-analysis. The green-dashed lines represent the conventional (&#945; = 5%) boundaries for statistical significance. The two pieces of red inward-sloping lines represent the trial sequential monitoring boundaries.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABAgAAALTCAYAAACbsDDMAACAAElEQVR42uzdB3wUZf7HcVBEPQsq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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-07-10 08:00:00 +0200" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2016-09-09 12:04:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<APPENDIX ID="APP-01" MODIFIED="2016-09-09 12:04:08 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2008-11-10 11:56:33 +0100" MODIFIED_BY="dimitrinka nikolova">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-09 12:04:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Date of search</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 July 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Anti-inflammatory or NSAID and (biliary colic or gall bladder or cholelithiasis)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2016, Issue 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees<BR/>#2 (anti-inflammatory agent) and (non-steroid*)<BR/>#3 NSAID*<BR/>#4 (#1 OR #2 OR #3)<BR/>#5 MeSH descriptor Biliary Tract Diseases explode all trees<BR/>#6 MeSH descriptor Colic explode all trees<BR/>#7 (#5 AND #6)<BR/>#8 (biliary colic*)<BR/>#9 (#7 OR #8)<BR/>#10 (#4 AND #9)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to 31 July 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "Anti-Inflammatory-Agents-Non-Steroidal"/ all subheadings<BR/>#2 non-steroid* anti-inflammatory or antinflammatory drug* or antinflammatory agent* or NSAIDs or non steroid* antinflammatory<BR/>#3 #1 or #2<BR/>#4 biliary colic* or biliary disease* or biliary pain*<BR/>#5 biliary complication* or biliary colic* complication* or acute cholecystitis or cholelithiasis-related complication* or acute pancreatitis or cholangitis or jaundice<BR/>#6 #4 or #5<BR/>#7 #3 and #6<BR/>#8 random* or placebo* or blind* or meta-analys* or Randomized controlled trial* or randomised clinical trial or controlled trial* or quasi randomized trial*<BR/>#9 #7 and #8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Embase (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to 31 July 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "antiinflammatory-agent"/ all subheadings<BR/>#2 antinflammatory drug* or antinflammatory agent* or NSAIDs or non steroid* antinflammatory<BR/>#3 #1 or #2<BR/>#4 biliary colic* or biliary disease* or biliary pain or biliary complication* or biliary colic* complication* or acute cholecystitis or cholelithiasis-related complication* or acute pancreatitis or cholangitis or jaundice<BR/>#5 explode "colic"/ all subheadings<BR/>#6 explode "biliary-tract-disease"/ all subheadings<BR/>#7 #4 or #5 or #6<BR/>#8 #3 and #7<BR/>#9 random* or placebo* or meta-analys* or blind* or Randomized controlled trial* or randomised clinical trial or controlled trial* or quasi randomized trial*<BR/>#10 #8 and #9<BR/>#11 animal*<BR/>#12 #10 not #11</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (Web of Science)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to 31 July 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#5 #3 and #4<BR/>#4 TS=biliary colic*<BR/>#3 6#1 or #2<BR/>#2 TS=NSAID*<BR/>#1 TS=(Anti-Inflammatory Agent* and Non-Steroid*)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2015-07-10 08:00:00 +0200" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 studies included for analysis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 duplicates&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;264 studies excluded as irrelevant (by reading the abstract in 258 studies and the full text in 6 studies)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;278 studies identified by the search strategy&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 ongoing study identified on clinicaltrials.gov&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>